0001541157 2026-01-01 2026-03-31 0001541157 AKTX:AmericanDepositarySharesEachRepresenting80000OrdinarySharesParValue0.000000005PerShareMember 2026-01-01 2026-03-31 0001541157 AKTX:OrdinaryShares0.000000005ParValuePerShareMember 2026-01-01 2026-03-31 0001541157 2026-05-19 0001541157 2026-03-31 0001541157 2025-12-31 0001541157 2025-01-01 2025-03-31 0001541157 us-gaap:CommonStockMember 2025-12-31 0001541157 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001541157 us-gaap:CapitalUnitsMember 2025-12-31 0001541157 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-31 0001541157 us-gaap:RetainedEarningsMember 2025-12-31 0001541157 us-gaap:CommonStockMember 2024-12-31 0001541157 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001541157 us-gaap:CapitalUnitsMember 2024-12-31 0001541157 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001541157 us-gaap:RetainedEarningsMember 2024-12-31 0001541157 2024-12-31 0001541157 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001541157 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001541157 us-gaap:CapitalUnitsMember 2026-01-01 2026-03-31 0001541157 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-01-01 2026-03-31 0001541157 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001541157 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001541157 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001541157 us-gaap:CapitalUnitsMember 2025-01-01 2025-03-31 0001541157 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001541157 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001541157 us-gaap:CommonStockMember 2026-03-31 0001541157 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001541157 us-gaap:CapitalUnitsMember 2026-03-31 0001541157 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-03-31 0001541157 us-gaap:RetainedEarningsMember 2026-03-31 0001541157 us-gaap:CommonStockMember 2025-03-31 0001541157 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001541157 us-gaap:CapitalUnitsMember 2025-03-31 0001541157 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001541157 us-gaap:RetainedEarningsMember 2025-03-31 0001541157 2025-03-31 0001541157 2025-12-14 0001541157 us-gaap:CommonStockMember 2025-12-15 0001541157 us-gaap:DeferredCompensationShareBasedPaymentsMember 2025-12-15 2025-12-15 0001541157 AKTX:ADSMember us-gaap:CommonStockMember 2026-03-31 0001541157 srt:MaximumMember AKTX:ADSMember us-gaap:CommonStockMember 2026-03-31 0001541157 srt:MinimumMember 2025-11-24 0001541157 AKTX:AKTX101Member AKTX:GrossCarryingAmountMember 2026-03-31 0001541157 AKTX:AKTX101Member AKTX:CumulativeImpairmentChargeMember 2026-03-31 0001541157 AKTX:AKTX101Member AKTX:NetBookValueMember 2026-03-31 0001541157 AKTX:GrossCarryingAmountMember 2026-03-31 0001541157 AKTX:CumulativeImpairmentChargeMember 2026-03-31 0001541157 AKTX:NetBookValueMember 2026-03-31 0001541157 AKTX:AKTX101Member AKTX:GrossCarryingAmountMember 2025-12-31 0001541157 AKTX:AKTX101Member AKTX:CumulativeImpairmentChargeMember 2025-12-31 0001541157 AKTX:AKTX101Member AKTX:NetBookValueMember 2025-12-31 0001541157 AKTX:PHP303Member AKTX:GrossCarryingAmountMember 2025-12-31 0001541157 AKTX:PHP303Member AKTX:CumulativeImpairmentChargeMember 2025-12-31 0001541157 AKTX:PHP303Member AKTX:NetBookValueMember 2025-12-31 0001541157 AKTX:GrossCarryingAmountMember 2025-12-31 0001541157 AKTX:CumulativeImpairmentChargeMember 2025-12-31 0001541157 AKTX:NetBookValueMember 2025-12-31 0001541157 AKTX:SeptemberTwoThousandTwentyFourNotePayableMember 2024-11-30 0001541157 AKTX:SeptemberTwoThousandTwentyFourNotePayableMember 2026-01-01 2026-03-31 0001541157 AKTX:SeptemberTwoThousandTwentyFourNotePayableMember 2025-12-31 0001541157 AKTX:SeptemberTwoThousandTwentyFourNotePayableMember 2026-03-31 0001541157 AKTX:AprilTwoThousandTwentyThreeConvertibleNotesMember 2024-11-30 0001541157 AKTX:AprilTwoThousandTwentyThreeConvertibleNotesAndWarrantsAmendmentMember AKTX:LetterAgreementMember 2025-09-19 0001541157 AKTX:AprilTwoThousandTwentyThreePeakBioConvertibleNoteholderWarrantsMember AKTX:LetterAgreementMember 2025-09-19 0001541157 AKTX:AprilTwoThousandTwentyThreeConvertibleNotesAndWarrantsAmendmentMember 2025-09-19 2025-09-19 0001541157 AKTX:AprilTwoThousandTwentyThreePeakBioConvertibleNoteholderWarrantsMember 2025-09-19 0001541157 AKTX:AprilTwoThousandTwentyThreePeakBioConvertibleNoteholderWarrantsMember 2025-09-19 2025-09-19 0001541157 2024-11-30 0001541157 us-gaap:MeasurementInputSharePriceMember 2024-11-30 0001541157 us-gaap:MeasurementInputPriceVolatilityMember 2024-11-30 0001541157 us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-11-30 0001541157 us-gaap:MeasurementInputExpectedTermMember 2024-11-30 0001541157 2024-11-01 2024-11-30 0001541157 AKTX:AprilTwoThousandTwentyThreeConvertibleNoteMember 2025-01-01 2025-03-31 0001541157 AKTX:AprilTwoThousandTwentyThreeConvertibleNoteMember 2026-01-01 2026-03-31 0001541157 AKTX:AprilTwoThousandTwentyThreeConvertibleNoteMember 2026-03-31 0001541157 AKTX:AprilTwoThousandTwentyThreeConvertibleNoteMember 2025-12-31 0001541157 dei:AdrMember AKTX:OrdinarySharesMember 2026-03-31 0001541157 AKTX:ELOCPurchaseAgreementMember AKTX:WhiteLionCapitalLLCMember 2025-08-29 2025-08-29 0001541157 2025-08-29 0001541157 2025-08-29 2025-08-29 0001541157 us-gaap:CommonStockMember AKTX:ELOCPurchaseAgreementMember 2025-08-29 0001541157 AKTX:ELOCPurchaseAgreementMember 2025-08-29 0001541157 AKTX:ELOCPurchaseAgreementMember 2025-08-29 2025-08-29 0001541157 us-gaap:MeasurementInputSharePriceMember AKTX:ELOCPurchaseAgreementMember 2025-08-29 0001541157 us-gaap:MeasurementInputPriceVolatilityMember AKTX:ELOCPurchaseAgreementMember 2025-08-29 0001541157 us-gaap:MeasurementInputRiskFreeInterestRateMember AKTX:ELOCPurchaseAgreementMember 2025-08-29 0001541157 us-gaap:MeasurementInputDiscountRateMember AKTX:ELOCPurchaseAgreementMember 2025-08-29 0001541157 AKTX:OrdinarySharesMember us-gaap:PrivatePlacementMember 2025-12-01 2025-12-31 0001541157 AKTX:OrdinarySharesMember 2025-12-01 2025-12-31 0001541157 AKTX:SeriesGWarrantsMember 2025-12-31 0001541157 AKTX:SeriesGWarrantsMember AKTX:ADSMember 2025-12-31 0001541157 AKTX:SeriesGWarrantMember 2025-12-31 0001541157 AKTX:ADSMember 2025-12-31 0001541157 2025-12-01 2025-12-31 0001541157 AKTX:SeriesGWarrantMember 2026-03-02 0001541157 AKTX:TwentyThousandTwentyFiveRegisteredDirectOfferingMember 2026-01-01 2026-03-31 0001541157 AKTX:DecemberTwoThousandAndTwentyFiveInvestorPrefundedWarrantMember 2026-03-31 0001541157 AKTX:DecemberTwoThousandAndTwentyFiveInvestorPrefundedWarrantMember 2025-12-31 0001541157 AKTX:AprilTwoThousandAndTwentyFiveInvestorPrefundedWarrantsMember 2026-03-31 0001541157 AKTX:AprilTwoThousandAndTwentyFiveInvestorPrefundedWarrantsMember 2025-12-31 0001541157 AKTX:OctoberTwoThousandAndTwentyThreeInvestorPrefundedMember 2026-03-31 0001541157 AKTX:OctoberTwoThousandAndTwentyThreeInvestorPrefundedMember 2025-12-31 0001541157 AKTX:DecemberTwoThousandAndTwentyFiveSeriesGInvestorWarrantsMember 2026-03-31 0001541157 AKTX:DecemberTwoThousandAndTwentyFiveSeriesGInvestorWarrantsMember 2025-12-31 0001541157 AKTX:DecemberTwoThousandAndTwentyFiveNoteWarrantsMember 2026-03-31 0001541157 AKTX:DecemberTwoThousandAndTwentyFiveNoteWarrantsMember 2025-12-31 0001541157 AKTX:DecemberTwoThousandAndTwentyFivePlacementAgentWarrantsMember 2026-03-31 0001541157 AKTX:DecemberTwoThousandAndTwentyFivePlacementAgentWarrantsMember 2025-12-31 0001541157 AKTX:AprilTwoThousandTwentyThreePeakBioWarrantsMember 2026-03-31 0001541157 AKTX:AprilTwoThousandTwentyThreePeakBioWarrantsMember 2025-12-31 0001541157 AKTX:MarchTwoThousandAndTwentyFiveSeriesAInvestorWarrantsMember 2026-03-31 0001541157 AKTX:MarchTwoThousandAndTwentyFiveSeriesAInvestorWarrantsMember 2025-12-31 0001541157 AKTX:MarchTwoThousandAndTwentyFiveInvestorWarrantsMember 2026-03-31 0001541157 AKTX:MarchTwoThousandAndTwentyFiveInvestorWarrantsMember 2025-12-31 0001541157 AKTX:AprilTwoThousandAndTwentyFiveSeriesAInvestorWarrantsMember 2026-03-31 0001541157 AKTX:AprilTwoThousandAndTwentyFiveSeriesAInvestorWarrantsMember 2025-12-31 0001541157 AKTX:AprilTwoThousandAndTwentyFiveInvestorWarrantsMember 2026-03-31 0001541157 AKTX:AprilTwoThousandAndTwentyFiveInvestorWarrantsMember 2025-12-31 0001541157 AKTX:OctoberTwoThousandAndTwentyFiveSeriesEInvestorWarrantsMember 2026-03-31 0001541157 AKTX:OctoberTwoThousandAndTwentyFiveSeriesEInvestorWarrantsMember 2025-12-31 0001541157 AKTX:OctoberTwoThousandAndTwentyFiveSeriesFInvestorWarrantsMember 2026-03-31 0001541157 AKTX:OctoberTwoThousandAndTwentyFiveSeriesFInvestorWarrantsMember 2025-12-31 0001541157 AKTX:OctoberTwoThousandAndTwentyFivePlacementAgentWarrantsMember 2026-03-31 0001541157 AKTX:OctoberTwoThousandAndTwentyFivePlacementAgentWarrantsMember 2025-12-31 0001541157 AKTX:MayTwoThousandAndTwentyFourInvestorWarrantsMember 2026-03-31 0001541157 AKTX:MayTwoThousandAndTwentyFourInvestorWarrantsMember 2025-12-31 0001541157 AKTX:MarchTwoThousandAndTwentyFourPlacementAgentWarrantsMember 2026-03-31 0001541157 AKTX:MarchTwoThousandAndTwentyFourPlacementAgentWarrantsMember 2025-12-31 0001541157 AKTX:MayTwoThousandAndTwentyFourPlacementAgentWarrantsMember 2026-03-31 0001541157 AKTX:MayTwoThousandAndTwentyFourPlacementAgentWarrantsMember 2025-12-31 0001541157 AKTX:NovemberTwoThousandAndTwentyFourInvestorWarrantsMember 2026-03-31 0001541157 AKTX:NovemberTwoThousandAndTwentyFourInvestorWarrantsMember 2025-12-31 0001541157 AKTX:OctoberTwoThousandAndTwentyThreePlacementAgentWarrantsMember 2026-03-31 0001541157 AKTX:OctoberTwoThousandAndTwentyThreePlacementAgentWarrantsMember 2025-12-31 0001541157 AKTX:MarchTwoThousandAndTwentyTwoInvestorWarrantsMember 2026-03-31 0001541157 AKTX:MarchTwoThousandAndTwentyTwoInvestorWarrantsMember 2025-12-31 0001541157 AKTX:MarchTwoThousandAndTwentyTwoPlacementAgentWarrantsMember 2026-03-31 0001541157 AKTX:MarchTwoThousandAndTwentyTwoPlacementAgentWarrantsMember 2025-12-31 0001541157 AKTX:DecemberTwoThousandAndTwentyOneInvestorWarrantsMember 2026-03-31 0001541157 AKTX:DecemberTwoThousandAndTwentyOneInvestorWarrantsMember 2025-12-31 0001541157 AKTX:DecemberTwoThousandAndTwentyOnePlacementAgentWarrantsMember 2026-03-31 0001541157 AKTX:DecemberTwoThousandAndTwentyOnePlacementAgentWarrantsMember 2025-12-31 0001541157 AKTX:JulyTwoThousandAndTwentyOnePlacementAgentWarrantsMember 2026-03-31 0001541157 AKTX:JulyTwoThousandAndTwentyOnePlacementAgentWarrantsMember 2025-12-31 0001541157 AKTX:AprilTwoThousandTwentyThreePeakBioWarrantsOneMember 2026-03-31 0001541157 AKTX:AprilTwoThousandTwentyThreePeakBioWarrantsOneMember 2025-12-31 0001541157 AKTX:SeptemberTwoThousandTwentyTwoSeriesBInvestorWarrantsMember 2026-03-31 0001541157 AKTX:SeptemberTwoThousandTwentyTwoSeriesBInvestorWarrantsMember 2025-12-31 0001541157 AKTX:NovemberTwoThousandTwentyTwoPeakBioWarrantsMember 2026-03-31 0001541157 AKTX:NovemberTwoThousandTwentyTwoPeakBioWarrantsMember 2025-12-31 0001541157 srt:ScenarioPreviouslyReportedMember us-gaap:WarrantMember 2025-12-31 0001541157 srt:ScenarioPreviouslyReportedMember us-gaap:WarrantMember 2026-01-01 2026-03-31 0001541157 srt:ScenarioPreviouslyReportedMember us-gaap:WarrantMember 2026-03-31 0001541157 AKTX:EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember 2025-12-31 0001541157 AKTX:EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember 2025-01-01 2025-12-31 0001541157 AKTX:EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember 2026-01-01 2026-03-31 0001541157 AKTX:EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember 2026-03-31 0001541157 us-gaap:RestrictedStockUnitsRSUMember 2026-03-31 0001541157 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2026-03-31 0001541157 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-03-31 0001541157 us-gaap:PerformanceSharesMember 2026-01-01 2026-03-31 0001541157 AKTX:UnvestedStockOptionMember 2026-03-31 0001541157 AKTX:UnvestedStockOptionMember 2026-01-01 2026-03-31 0001541157 us-gaap:RestrictedStockUnitsRSUMember 2025-12-31 0001541157 AKTX:ResearchAndDevelopmentExpensesMember 2026-01-01 2026-03-31 0001541157 AKTX:ResearchAndDevelopmentExpensesMember 2025-01-01 2025-03-31 0001541157 AKTX:SellingGeneralAndAdministrativeExpenseMember 2026-01-01 2026-03-31 0001541157 AKTX:SellingGeneralAndAdministrativeExpenseMember 2025-01-01 2025-03-31 0001541157 AKTX:AprilTwoThousandTwentyThreePeakBioWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001541157 AKTX:AprilTwoThousandTwentyThreePeakBioWarrantsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001541157 AKTX:AprilTwoThousandTwentyThreePeakBioWarrantsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001541157 AKTX:AprilTwoThousandTwentyThreePeakBioWarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001541157 us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001541157 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001541157 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001541157 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2026-03-31 0001541157 AKTX:AprilTwoThousandTwentyThreePeakBioWarrantsMember us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001541157 AKTX:AprilTwoThousandTwentyThreePeakBioWarrantsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001541157 AKTX:AprilTwoThousandTwentyThreePeakBioWarrantsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001541157 AKTX:AprilTwoThousandTwentyThreePeakBioWarrantsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001541157 AKTX:SeptemberTwoThousandTwentyTwoSeriesBMember us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001541157 AKTX:SeptemberTwoThousandTwentyTwoSeriesBMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001541157 AKTX:SeptemberTwoThousandTwentyTwoSeriesBMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001541157 AKTX:SeptemberTwoThousandTwentyTwoSeriesBMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001541157 us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001541157 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001541157 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001541157 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001541157 AKTX:SeptemberTwoThousandTwentyTwoSeriesBMember us-gaap:FairValueInputsLevel3Member 2024-12-31 0001541157 AKTX:NovemberTwoThousandTwentyTwoPeakBioWarrantsMember us-gaap:FairValueInputsLevel3Member 2024-12-31 0001541157 AKTX:AprilTwoThousandTwentyThreePeakBioWarrantsMember us-gaap:FairValueInputsLevel3Member 2024-12-31 0001541157 AKTX:TotalWarrantLiabilityMember us-gaap:FairValueInputsLevel3Member 2024-12-31 0001541157 AKTX:DerivativeLiabilityMember us-gaap:FairValueInputsLevel3Member 2024-12-31 0001541157 AKTX:SeptemberTwoThousandTwentyTwoSeriesBMember us-gaap:FairValueInputsLevel3Member 2025-01-01 2025-03-31 0001541157 AKTX:NovemberTwoThousandTwentyTwoPeakBioWarrantsMember us-gaap:FairValueInputsLevel3Member 2025-01-01 2025-03-31 0001541157 AKTX:AprilTwoThousandTwentyThreePeakBioWarrantsMember us-gaap:FairValueInputsLevel3Member 2025-01-01 2025-03-31 0001541157 AKTX:TotalWarrantLiabilityMember us-gaap:FairValueInputsLevel3Member 2025-01-01 2025-03-31 0001541157 AKTX:DerivativeLiabilityMember us-gaap:FairValueInputsLevel3Member 2025-01-01 2025-03-31 0001541157 AKTX:SeptemberTwoThousandTwentyTwoSeriesBMember us-gaap:FairValueInputsLevel3Member 2025-03-31 0001541157 AKTX:NovemberTwoThousandTwentyTwoPeakBioWarrantsMember us-gaap:FairValueInputsLevel3Member 2025-03-31 0001541157 AKTX:AprilTwoThousandTwentyThreePeakBioWarrantsMember us-gaap:FairValueInputsLevel3Member 2025-03-31 0001541157 AKTX:TotalWarrantLiabilityMember us-gaap:FairValueInputsLevel3Member 2025-03-31 0001541157 AKTX:DerivativeLiabilityMember us-gaap:FairValueInputsLevel3Member 2025-03-31 0001541157 AKTX:SeptemberTwoThousandTwentyTwoSeriesBMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0001541157 AKTX:NovemberTwoThousandTwentyTwoPeakBioWarrantsMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0001541157 AKTX:AprilTwoThousandTwentyThreePeakBioWarrantsMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0001541157 AKTX:TotalWarrantLiabilityMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0001541157 AKTX:DerivativeLiabilityMember us-gaap:FairValueInputsLevel3Member 2025-12-31 0001541157 AKTX:SeptemberTwoThousandTwentyTwoSeriesBMember us-gaap:FairValueInputsLevel3Member 2026-01-01 2026-03-31 0001541157 AKTX:NovemberTwoThousandTwentyTwoPeakBioWarrantsMember us-gaap:FairValueInputsLevel3Member 2026-01-01 2026-03-31 0001541157 AKTX:AprilTwoThousandTwentyThreePeakBioWarrantsMember us-gaap:FairValueInputsLevel3Member 2026-01-01 2026-03-31 0001541157 AKTX:TotalWarrantLiabilityMember us-gaap:FairValueInputsLevel3Member 2026-01-01 2026-03-31 0001541157 AKTX:DerivativeLiabilityMember us-gaap:FairValueInputsLevel3Member 2026-01-01 2026-03-31 0001541157 AKTX:SeptemberTwoThousandTwentyTwoSeriesBMember us-gaap:FairValueInputsLevel3Member 2026-03-31 0001541157 AKTX:NovemberTwoThousandTwentyTwoPeakBioWarrantsMember us-gaap:FairValueInputsLevel3Member 2026-03-31 0001541157 AKTX:AprilTwoThousandTwentyThreePeakBioWarrantsMember us-gaap:FairValueInputsLevel3Member 2026-03-31 0001541157 AKTX:TotalWarrantLiabilityMember us-gaap:FairValueInputsLevel3Member 2026-03-31 0001541157 AKTX:DerivativeLiabilityMember us-gaap:FairValueInputsLevel3Member 2026-03-31 0001541157 AKTX:SeptemberTwoThousandTwentyTwoSeriesBMember us-gaap:MeasurementInputSharePriceMember 2026-03-31 0001541157 AKTX:NovemberTwoThousandTwentyTwoWarrantsMember us-gaap:MeasurementInputSharePriceMember 2026-03-31 0001541157 AKTX:AprilTwoThousandTwentyThreeWarrantsMember us-gaap:MeasurementInputSharePriceMember 2026-03-31 0001541157 AKTX:SeptemberTwoThousandTwentyTwoSeriesBMember us-gaap:MeasurementInputSharePriceMember 2025-12-31 0001541157 AKTX:NovemberTwoThousandTwentyTwoWarrantsMember us-gaap:MeasurementInputSharePriceMember 2025-12-31 0001541157 AKTX:AprilTwoThousandTwentyThreeWarrantsMember us-gaap:MeasurementInputSharePriceMember 2025-12-31 0001541157 AKTX:SeptemberTwoThousandTwentyTwoSeriesBMember us-gaap:MeasurementInputExercisePriceMember 2026-03-31 0001541157 AKTX:NovemberTwoThousandTwentyTwoWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2026-03-31 0001541157 AKTX:AprilTwoThousandTwentyThreeWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2026-03-31 0001541157 AKTX:SeptemberTwoThousandTwentyTwoSeriesBMember us-gaap:MeasurementInputExercisePriceMember 2025-12-31 0001541157 AKTX:NovemberTwoThousandTwentyTwoWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2025-12-31 0001541157 AKTX:AprilTwoThousandTwentyThreeWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2025-12-31 0001541157 AKTX:SeptemberTwoThousandTwentyTwoSeriesBMember us-gaap:MeasurementInputExpectedTermMember 2026-03-31 0001541157 AKTX:NovemberTwoThousandTwentyTwoWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2026-03-31 0001541157 AKTX:AprilTwoThousandTwentyThreeWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2026-03-31 0001541157 AKTX:SeptemberTwoThousandTwentyTwoSeriesBMember us-gaap:MeasurementInputExpectedTermMember 2025-12-31 0001541157 AKTX:NovemberTwoThousandTwentyTwoWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2025-12-31 0001541157 AKTX:AprilTwoThousandTwentyThreeWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2025-12-31 0001541157 AKTX:SeptemberTwoThousandTwentyTwoSeriesBMember us-gaap:MeasurementInputPriceVolatilityMember 2026-03-31 0001541157 AKTX:NovemberTwoThousandTwentyTwoWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2026-03-31 0001541157 AKTX:AprilTwoThousandTwentyThreeWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2026-03-31 0001541157 AKTX:SeptemberTwoThousandTwentyTwoSeriesBMember us-gaap:MeasurementInputPriceVolatilityMember 2025-12-31 0001541157 AKTX:NovemberTwoThousandTwentyTwoWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2025-12-31 0001541157 AKTX:AprilTwoThousandTwentyThreeWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2025-12-31 0001541157 AKTX:SeptemberTwoThousandTwentyTwoSeriesBMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-03-31 0001541157 AKTX:NovemberTwoThousandTwentyTwoWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-03-31 0001541157 AKTX:AprilTwoThousandTwentyThreeWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-03-31 0001541157 AKTX:SeptemberTwoThousandTwentyTwoSeriesBMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-12-31 0001541157 AKTX:NovemberTwoThousandTwentyTwoWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-12-31 0001541157 AKTX:AprilTwoThousandTwentyThreeWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-12-31 0001541157 AKTX:SeptemberTwoThousandTwentyTwoSeriesBMember us-gaap:MeasurementInputExpectedDividendRateMember 2026-03-31 0001541157 AKTX:NovemberTwoThousandTwentyTwoWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2026-03-31 0001541157 AKTX:AprilTwoThousandTwentyThreeWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2026-03-31 0001541157 AKTX:SeptemberTwoThousandTwentyTwoSeriesBMember us-gaap:MeasurementInputExpectedDividendRateMember 2025-12-31 0001541157 AKTX:NovemberTwoThousandTwentyTwoWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2025-12-31 0001541157 AKTX:AprilTwoThousandTwentyThreeWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2025-12-31 0001541157 us-gaap:MeasurementInputSharePriceMember AKTX:ELOCPurchaseAgreementMember 2025-12-31 0001541157 us-gaap:MeasurementInputPriceVolatilityMember AKTX:ELOCPurchaseAgreementMember 2025-12-31 0001541157 us-gaap:MeasurementInputRiskFreeInterestRateMember AKTX:ELOCPurchaseAgreementMember 2025-12-31 0001541157 us-gaap:MeasurementInputDiscountRateMember AKTX:ELOCPurchaseAgreementMember 2025-12-31 0001541157 us-gaap:MeasurementInputSharePriceMember AKTX:ELOCPurchaseAgreementMember 2026-03-31 0001541157 us-gaap:MeasurementInputPriceVolatilityMember AKTX:ELOCPurchaseAgreementMember 2026-03-31 0001541157 us-gaap:MeasurementInputRiskFreeInterestRateMember AKTX:ELOCPurchaseAgreementMember 2026-03-31 0001541157 us-gaap:MeasurementInputDiscountRateMember AKTX:ELOCPurchaseAgreementMember 2026-03-31 0001541157 us-gaap:FairValueInputsLevel3Member 2026-01-01 2026-03-31 0001541157 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-03-31 0001541157 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0001541157 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-03-31 0001541157 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-03-31 0001541157 us-gaap:WarrantMember 2026-01-01 2026-03-31 0001541157 us-gaap:WarrantMember 2025-01-01 2025-03-31 0001541157 us-gaap:ConvertibleDebtSecuritiesMember 2026-01-01 2026-03-31 0001541157 us-gaap:ConvertibleDebtSecuritiesMember 2025-01-01 2025-03-31 0001541157 AKTX:ImpairmentLossOnOtherIntangibleAssetsMember 2026-01-01 2026-03-31 0001541157 AKTX:ExpectedCurrentYearLossAndHistoricalLossMember 2026-01-01 2026-03-31 0001541157 AKTX:ExpectedCurrentYearLossAndHistoricalLossMember 2025-01-01 2025-03-31 0001541157 AKTX:ADCPreClinicalDevelopmentMember AKTX:SignificantSegmentExpenseCategoryMember 2026-01-01 2026-03-31 0001541157 AKTX:ADCPreClinicalDevelopmentMember AKTX:SignificantSegmentExpenseCategoryMember 2025-01-01 2025-03-31 0001541157 AKTX:HSCTTMAAK901ProgramMember AKTX:SignificantSegmentExpenseCategoryMember 2026-01-01 2026-03-31 0001541157 AKTX:HSCTTMAAK901ProgramMember AKTX:SignificantSegmentExpenseCategoryMember 2025-01-01 2025-03-31 0001541157 AKTX:ChemistryManufacturingAndControlMember AKTX:SignificantSegmentExpenseCategoryMember 2026-01-01 2026-03-31 0001541157 AKTX:ChemistryManufacturingAndControlMember AKTX:SignificantSegmentExpenseCategoryMember 2025-01-01 2025-03-31 0001541157 AKTX:OtherExternalDevelopmentExpenseIncomeMember AKTX:SignificantSegmentExpenseCategoryMember 2026-01-01 2026-03-31 0001541157 AKTX:OtherExternalDevelopmentExpenseIncomeMember AKTX:SignificantSegmentExpenseCategoryMember 2025-01-01 2025-03-31 0001541157 AKTX:InternalAndOtherResearchAndDevelopmentExpenseMember AKTX:SignificantSegmentExpenseCategoryMember 2026-01-01 2026-03-31 0001541157 AKTX:InternalAndOtherResearchAndDevelopmentExpenseMember AKTX:SignificantSegmentExpenseCategoryMember 2025-01-01 2025-03-31 0001541157 AKTX:SignificantSegmentExpenseCategoryMember 2026-01-01 2026-03-31 0001541157 AKTX:SignificantSegmentExpenseCategoryMember 2025-01-01 2025-03-31 0001541157 us-gaap:RelatedPartyMember 2026-03-31 0001541157 us-gaap:RelatedPartyMember 2025-12-31 0001541157 srt:MaximumMember 2025-01-01 2025-03-31 0001541157 srt:MaximumMember 2026-01-01 2026-03-31 0001541157 us-gaap:WithdrawalFromMultiemployerDefinedBenefitPlanMember 2026-01-01 2026-03-31 0001541157 us-gaap:WithdrawalFromMultiemployerDefinedBenefitPlanMember us-gaap:ForeignPlanMember 2026-01-01 2026-03-31 0001541157 srt:MaximumMember us-gaap:WithdrawalFromMultiemployerDefinedBenefitPlanMember 2025-01-01 2025-03-31 0001541157 srt:MaximumMember us-gaap:WithdrawalFromMultiemployerDefinedBenefitPlanMember 2026-01-01 2026-03-31 0001541157 AKTX:BayerAcquisitionAgreementMember 2026-03-31 0001541157 srt:MaximumMember 2025-05-31 0001541157 AKTX:SettlementAgreementMember 2026-01-01 2026-03-31 iso4217:USD shares iso4217:USD shares pure AKTX:Integer false --12-31 Q1 0001541157 10-Q true 2026-03-31 2026 false 001-36288 Akari Therapeutics, Plc X0 98-1034922 401 East Jackson Street Suite 3300 Tampa FL 33602 (929) 274-7510 American Depositary Shares, each representing 80,000 Ordinary Shares, par value $0.000000005 per share AKTX NASDAQ Ordinary Shares, $0.000000005 par value per share* AKTX NASDAQ Yes Yes Non-accelerated Filer true false false 91567009533 2768000 5203000 60000 60000 731000 185000 30000 14000 3589000 5462000 8430000 30300000 34000000 33889000 47892000 8641000 8770000 3328000 2342000 683000 673000 49000 81000 17000 61000 697000 424000 13415000 12351000 230000 31000 6094000 6952000 19509000 19564000 0.000000005 0.000000005 761963201733 761963201733 91567009533 91567009533 90536879533 90536879533 234811000 234318000 59342000 59342000 -768000 -782000 -279005000 -264550000 14380000 28328000 33889000 47892000 1459000 813000 2169000 2712000 3700000 8430000 15758000 3525000 -15758000 -3525000 61000 55000 167000 54000 44000 -54000 230000 64000 -125000 444000 -180000 -15314000 -3705000 -859000 -14455000 -3705000 -0.00 -0.00 -0.00 -0.00 118757013401 118757013401 54588283841 54588283841 -14455000 -3705000 14000 -35000 14000 -35000 -14441000 -3740000 90536879533 234318000 59342000 -782000 -264550000 28328000 1030130000 188000 188000 305000 305000 14000 14000 -14455000 -14455000 91567009533 234811000 59342000 -768000 -279005000 14380000 53186919523 5319000 212706000 52194000 -738000 -247252000 22229000 53186919523 5319000 212706000 52194000 -738000 -247252000 22229000 4566062000 457000 1785000 2242000 1015000 1015000 -35000 -35000 -3705000 -3705000 57752981523 5776000 215506000 52194000 -773000 -250957000 21746000 57752981523 5776000 215506000 52194000 -773000 -250957000 21746000 -14455000 -3705000 305000 1015000 10000 167000 54000 44000 -54000 3700000 8430000 230000 -859000 15000 27000 94000 -84000 931000 483000 -2488000 -2150000 188000 1557000 1090000 -33000 -406000 102000 108000 53000 2133000 -2435000 -17000 5263000 2659000 2828000 2642000 2768000 2582000 60000 60000 2828000 2642000 315000 140000 1000000 469000 499000 6000 7000 <p id="xdx_80C_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_z0Dm6jenefbl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1. <span id="xdx_829_zGeMUjP6Bi24">Description of Business</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Business Overview</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Akari Therapeutics, Plc, (the “Company” or “Akari”) is incorporated in the United Kingdom. The Company is developing next-generation antibody-drug conjugates (“ADCs”) through its proprietary technology platform that enables the Company to establish a pipeline of ADC candidates that target and kill cancer cells and stimulate the immune system, all while overcoming the limitations inherent in existing therapies. The Company’s activities since inception have consisted of performing research and development activities and raising capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to a number of risks similar to those of preclinical and clinical stage companies, including dependence on key individuals, uncertainty of product development and generation of revenues, dependence on outside sources of capital, risks associated with clinical trials of products, dependence on third-party collaborators for research and development operations, need for marketing authorization of products, risks associated with protection of intellectual property, and competition with larger, better-capitalized companies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To fully execute its business plan, the Company will need, among other things, to complete its research and development efforts, preclinical and regulatory activities, and clinical trials. These activities may take several years and will require significant operating and capital expenditures in the foreseeable future. There can be no assurance that these activities will be successful. If the Company is not successful in these activities it could delay, limit, reduce or terminate its preclinical studies or other discovery and research activities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Basis of presentation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and the rules and regulations of the SEC and assumes that the Company will continue to operate as a going concern. Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, including normal and recurring adjustments, which the Company considers necessary for the fair statement of financial information. The results of operations and comprehensive loss for the three months ended March 31, 2026, are not necessarily indicative of expected results for the fiscal year ending December 31, 2026, or any other future period. The condensed consolidated balance sheet at December 31, 2025, has been derived from the audited consolidated financial statements at that date. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements as of December 31, 2025 and notes thereto included in its Form 10-K, as filed with the SEC on March 30, 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of estimates</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the Company’s condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets, liabilities, expenses and related disclosures. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the valuation of warrant liabilities and the impairment assessment of goodwill and indefinite-lived intangible assets. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed considering changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Liquidity and Financial Condition</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 205-40, <i>Presentation of Financial Statements—Going Concern</i>, which requires management to assess the Company’s ability to continue as a going concern within one year after the date the consolidated financial statements are issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has incurred substantial losses and negative cash flows since inception and had an accumulated deficit of $<span id="xdx_905_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20260331_zbBspvVGlY95" title="Accumulated deficit">279.0</span> million as of March 31, 2026. The Company’s cash balance of $<span id="xdx_902_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20260331_zOTcYnEX84m2" title="Cash">2.8</span> million as of March 31, 2026 is not sufficient to fund its operations for the one-year period after the date these condensed consolidated financial statements are issued. These factors raise substantial doubt about the Company’s ability to continue as a going concern for at least a one-year period following the issuance of these condensed consolidated financial statements. The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in research and development. The Company is subject to a number of risks and uncertainties similar to those of other companies of the same size within the biotechnology industry, such as uncertainty of preclinical research outcomes, uncertainty of additional funding, and history of operating losses. Substantial additional financing will be needed by the Company to fund its operations. Management is currently evaluating different strategies to obtain the required funding for future operations. These strategies may include but are not limited to private placements and/or public offerings of equity and/or debt securities, and strategic research and development collaborations and/or similar arrangements. There can be no assurance that these future funding efforts will be successful.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Par Value Change</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">Effective December 15, 2025, shareholders approved to sub-divide each of the ordinary shares with a par value of $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20251214_znPy4PsF7kp4" title="Ordinary shares, par value">0.0001</span> into one ordinary share with a par value $<span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20251215__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziZ3z2LaWtPe" title="Ordinary shares, par value">0.000000005</span> and <span id="xdx_908_eus-gaap--DeferredCompensationArrangementWithIndividualSharesIssued_pid_c20251215__20251215__us-gaap--StatementEquityComponentsAxis__us-gaap--DeferredCompensationShareBasedPaymentsMember_z6KnTfa8epB2" title="Deferred shares">19,999</span> deferred shares with a par value $<span id="xdx_907_eus-gaap--DeferredCompensationArrangementWithIndividualExercisePrice_pid_c20251215__20251215__us-gaap--StatementEquityComponentsAxis__us-gaap--DeferredCompensationShareBasedPaymentsMember_zlOLLjShvD55" title="Deferred share price">0.000000005</span> (the “Deferred Shares”), with such shares having the rights and being subject to the restrictions as set out in the new Articles of Association. As a result, the number of outstanding ordinary shares of the Company remained unchanged and there were <span id="xdx_907_eus-gaap--StockRepurchasedDuringPeriodShares_pid_c20251215__20251215__us-gaap--StatementEquityComponentsAxis__us-gaap--DeferredCompensationShareBasedPaymentsMember_zSTYxPvFFE07" title="Number of shares repurchased">1,429,517,750,998,477</span> Deferred Shares created. The deferred shares were repurchased and cancelled, and the Company issued 10 ordinary shares in connection with a buyback agreement. The rights attached to the ordinary shares, with a par value of $ <span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20251215__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAanTXze5yh4" title="Ordinary shares, par value">0.000000005</span> (including voting and dividend rights and rights on a return of capital) are identical in all respects to the previously outstanding ordinary shares with a par value of $<span id="xdx_90C_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20251214_zM5iOnwmuZ12" title="Ordinary shares, par value">0.0001</span>. The Deferred Shares have limited rights and are effectively valueless. There is no direct effect on the value of an ADS.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ADS Ratio Change</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective March 31, 2026, the Company changed the ratio of its American Depositary Shares (“ADS”) to ordinary shares, par value $<span id="xdx_90A_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJIBqSBqx1Rl" title="Ordinary shares, par value">0.000000005</span> per share, from one ADS representing <span id="xdx_902_eus-gaap--SharesOutstanding_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ADSMember_zJmrxcxSVdQi" title="Number of outstanding shares">2,000</span> ordinary shares to a new ratio of one ADS representing <span id="xdx_90B_eus-gaap--SharesOutstanding_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--ADSMember__srt--RangeAxis__srt--MaximumMember_zAhGr0QzfK31" title="Number of outstanding shares">80,000</span> ordinary shares (the “ADS Ratio Change”). All ADS and per ADS amounts in the accompanying condensed consolidated financial statements and notes thereto have been retroactively adjusted for all periods presented to reflect the ADS Ratio Change.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nasdaq Continued Listing Rules</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 24, 2025, the Company received a letter (“Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Capital Market (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price for the Company’s ADS had closed below $<span id="xdx_905_eus-gaap--SharePrice_iI_pid_c20251124__srt--RangeAxis__srt--MinimumMember_zpeokiI3zFSf" title="Share price">1.00</span> per share (the “Minimum Bid Requirement”) for the previous thirty consecutive business days. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company had 180 calendar days from the date of such notice, or until May 25, 2026, to regain compliance with the Minimum Bid Requirement. Following the successful completion of the ADS Ratio Change, the Company received a letter from the Nasdaq Office of General Counsel notifying the Company that the Company has regained compliance with the Minimum Bid Requirement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> -279000000.0 2800000 0.0001 0.000000005 19999 0.000000005 1429517750998477 0.000000005 0.0001 0.000000005 2000 80000 1.00 <p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_zjM17RYJokN5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2. <span id="xdx_825_zdFMLqqQUHjf">Summary of Significant Accounting Policies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The significant accounting policies and estimates used in the preparation of the accompanying unaudited condensed consolidated financial statements are described in the Company’s audited consolidated financial statements for the year ended December 31, 2025, included in the Company’s Annual Report on Form 10-K filed with the SEC on March 30, 2026. There have been no material changes in the Company’s significant accounting policies during the three months ended March 31, 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zB8rdMHCzAN2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zsNqfU5tGR88">Recent accounting pronouncements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our accompanying unaudited consolidated financial statements. During the first three months of 2026, there were no new accounting pronouncements issued or effective or are expected to have a material impact on our accompanying unaudited consolidated financial statements.</span></p> <p id="xdx_850_zCge4lU0Qdyj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zB8rdMHCzAN2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_zsNqfU5tGR88">Recent accounting pronouncements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our accompanying unaudited consolidated financial statements. During the first three months of 2026, there were no new accounting pronouncements issued or effective or are expected to have a material impact on our accompanying unaudited consolidated financial statements.</span></p> <p id="xdx_803_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zuw9VO48FZbd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 3. <span id="xdx_82D_zhvHGRAxhyy7">Goodwill and Intangible Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfOtherAssetsNoncurrentTextBlock_znyLCb6sjaA8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table presents information about the Company’s goodwill and IPR&amp;D assets:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B8_zpoG9oqqeA5i" style="display: none">Schedule of Other Intangible Assets</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20260331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--GrossCarryingAmountMember_zqmAh7zjUp37" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Carrying Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20260331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--CumulativeImpairmentChargeMember_zYrrPEPQkGq5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cumulative Impairment Charge</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20260331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--NetBookValueMember_zJXSVyAMs1Vj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net Book Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Carrying Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cumulative Impairment Charge</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net Book Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--OtherIntangibleAssetsNet_iI_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AKTX101Member_zvHrjanQvk98" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 46%; padding-bottom: 1pt">AKTX-101</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">34,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">3,700</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">30,300</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OtherIntangibleAssetsNet_iI_pn3n3_zfZvB239I10l" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 2.5pt">Total other intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">34,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,700</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">30,300</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--Goodwill_iI_pn3n3_zPPpYd3z4GZ5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 2.5pt">Goodwill</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,430</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,430</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0512">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="display: none; padding-left: 10pt; font-size: 10pt; padding-bottom: 1pt"> </td><td style="display: none; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; display: none; font-size: 10pt; text-align: left"> </td><td id="xdx_496_20251231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--GrossCarryingAmountMember_z4Nl23uiSd1e" style="border-bottom: Black 1pt solid; display: none; font-size: 10pt; text-align: right"> </td><td style="display: none; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="display: none; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; display: none; font-size: 10pt; text-align: left"> </td><td id="xdx_49A_20251231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--CumulativeImpairmentChargeMember_zCZ8998y0EHc" style="border-bottom: Black 1pt solid; display: none; font-size: 10pt; text-align: right"> </td><td style="display: none; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="display: none; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; display: none; font-size: 10pt; text-align: left"> </td><td id="xdx_493_20251231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--NetBookValueMember_zY5RhA0aD4Fd" style="border-bottom: Black 1pt solid; display: none; font-size: 10pt; text-align: right"> </td><td style="display: none; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Gross<br/> Carrying<br/> Amount</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Cumulative<br/> Impairment<br/> Charge</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Net Book<br/> Value</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--OtherIntangibleAssetsNet_iI_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AKTX101Member_zxkM63cMETSc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 46%; font-size: 10pt">AKTX-101</td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">34,000</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0515">—</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">34,000</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OtherIntangibleAssetsNet_iI_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PHP303Member_zc2i8TmKT7h2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; font-size: 10pt; padding-bottom: 1pt">PHP-303</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,180</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,180</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0520">—</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OtherIntangibleAssetsNet_iI_pn3n3_zELiNZltLjC7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total other intangible assets</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">39,180</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5,180</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">34,000</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"> </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"> </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"> </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--Goodwill_iI_pn3n3_zxTJcFOSNw34" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Goodwill</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">8,430</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0527">—</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">8,430</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zneDlePeEhU8" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 20.4pt"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s IPR&amp;D and goodwill are tested for impairment at least annually, or more frequently if impairment indicators are present. Due to a sustained decline in the Company’s ADS price and market capitalization during the three months ended March 31, 2026, a quantitative impairment test was triggered for both the Company’s IPR&amp;D and goodwill.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company first reviewed its AKTX-101 IPR&amp;D asset considering updated development and valuation assumptions. The updated assumptions included refinements to the expected development timelines and probability weighted cash flows to reflect current market conditions, capital availability considerations, and the heightened uncertainty inherent in advancing the program under these conditions, as well as an increase in the discount rate to reflect the overall risk profile of the asset. The estimated fair value of the IPR&amp;D asset was determined using the multi-period excess earnings method and requires management judgment with respect to forecasted gross revenues, revenue and expense growth rates, timing of clinical trials and overall probability of success, and the selection and use of an appropriate discount rate. As a result of the impairment analysis, the Company recorded an impairment charge of $<span id="xdx_906_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pn5n6_c20260101__20260331_zNuHXtJrx4G4">3.7</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million. </span>There was <span id="xdx_905_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_dxL_c20250101__20250331_zFqsmOwVrHUl" title="::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0530">no</span></span> impairment charge recognized on the AKTX 101-IPR&amp;D asset during the three months ended March 31, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company then performed a quantitative goodwill impairment assessment as of March 31, 2026. The fair value of the reporting unit was estimated using an income approach based on a discounted cash flow model and was compared to the Company’s overall market capitalization. As a result, the estimated fair value of the reporting unit was determined to be lower than its carrying value, and the Company recorded a non-cash goodwill impairment charge of $<span id="xdx_904_eus-gaap--GoodwillImpairmentLoss_pn5n6_c20260101__20260331_zIqXxrtvAkhf" title="Goodwill impairment charge">8.4</span> million in the condensed consolidated statement of operations and comprehensive loss during the three months ended March 31, 2026.</span> There was <span id="xdx_908_eus-gaap--GoodwillImpairmentLoss_dxL_c20250101__20250331_zCLikVJLBhYg" title="Goodwill impairment charge::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0534">no</span></span> impairment charge recognized on goodwill during the three months ended March 31, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfOtherAssetsNoncurrentTextBlock_znyLCb6sjaA8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table presents information about the Company’s goodwill and IPR&amp;D assets:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span id="xdx_8B8_zpoG9oqqeA5i" style="display: none">Schedule of Other Intangible Assets</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20260331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--GrossCarryingAmountMember_zqmAh7zjUp37" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Carrying Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20260331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--CumulativeImpairmentChargeMember_zYrrPEPQkGq5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cumulative Impairment Charge</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20260331__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--NetBookValueMember_zJXSVyAMs1Vj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net Book Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Gross Carrying Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Cumulative Impairment Charge</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Net Book Value</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--OtherIntangibleAssetsNet_iI_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AKTX101Member_zvHrjanQvk98" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 46%; padding-bottom: 1pt">AKTX-101</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">34,000</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">3,700</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 14%; text-align: right">30,300</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--OtherIntangibleAssetsNet_iI_pn3n3_zfZvB239I10l" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 2.5pt">Total other intangible assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">34,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,700</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">30,300</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--Goodwill_iI_pn3n3_zPPpYd3z4GZ5" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 2.5pt">Goodwill</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,430</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,430</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0512">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="display: none; padding-left: 10pt; font-size: 10pt; padding-bottom: 1pt"> </td><td style="display: none; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; display: none; font-size: 10pt; text-align: left"> </td><td id="xdx_496_20251231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--GrossCarryingAmountMember_z4Nl23uiSd1e" style="border-bottom: Black 1pt solid; display: none; font-size: 10pt; text-align: right"> </td><td style="display: none; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="display: none; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; display: none; font-size: 10pt; text-align: left"> </td><td id="xdx_49A_20251231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--CumulativeImpairmentChargeMember_zCZ8998y0EHc" style="border-bottom: Black 1pt solid; display: none; font-size: 10pt; text-align: right"> </td><td style="display: none; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="display: none; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; display: none; font-size: 10pt; text-align: left"> </td><td id="xdx_493_20251231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--NetBookValueMember_zY5RhA0aD4Fd" style="border-bottom: Black 1pt solid; display: none; font-size: 10pt; text-align: right"> </td><td style="display: none; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Gross<br/> Carrying<br/> Amount</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Cumulative<br/> Impairment<br/> Charge</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Net Book<br/> Value</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--OtherIntangibleAssetsNet_iI_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--AKTX101Member_zxkM63cMETSc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 46%; font-size: 10pt">AKTX-101</td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">34,000</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0515">—</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">34,000</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OtherIntangibleAssetsNet_iI_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PHP303Member_zc2i8TmKT7h2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; font-size: 10pt; padding-bottom: 1pt">PHP-303</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,180</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">5,180</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0520">—</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OtherIntangibleAssetsNet_iI_pn3n3_zELiNZltLjC7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total other intangible assets</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">39,180</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">5,180</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">34,000</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"> </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"> </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: right"> </td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--Goodwill_iI_pn3n3_zxTJcFOSNw34" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0pt; font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Goodwill</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">8,430</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0527">—</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">8,430</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> 34000000 3700000 30300000 34000000 3700000 30300000 8430000 8430000 34000000 34000000 5180000 5180000 39180000 5180000 34000000 8430000 8430000 3700000 8400000 <p id="xdx_800_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_z3NblsXmLLg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 4. <span id="xdx_822_z1l6DcUWov74">Accrued Expenses</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_89C_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zv2gqJMzje9h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses consisted of the following as of March 31, 2026, and December 31, 2025 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zmnXoqitY3G2" style="display: none">Summary of Accrued Expenses</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_498_20260331_zbyklydjme" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_491_20251231_zuaZcx9CcqR9" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn3n3_maALCzd48_zrPM8cU5W8dl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Employee compensation and benefits</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">888</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">780</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--AccruedExternalResearchAndDevelopmentExpenses_iI_pn3n3_maALCzd48_zngB5zZefxkb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">External research and development expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,043</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">299</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzd48_zZf9cED1dJQ" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Professional and consulting fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">892</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">814</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzd48_zhxqVY3bVgEe" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">505</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">449</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzd48_zyCm4NCVOGuj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,328</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,342</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zSVU4jOJpIfb" style="margin-top: 0; margin-bottom: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 5. <span id="xdx_82F_zUVom5xJaTph">Convertible Notes and Notes Payable</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>September 2024 Note Payable</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2024, the Company assumed a promissory note originally issued by Peak Bio in September 2024 in the amount of $<span id="xdx_900_eus-gaap--NotesPayableCurrent_iI_pn5n6_c20241130__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyFourNotePayableMember_zcS5Zd8YDYjf" title="Notes payable">0.3</span> million (the “September 2024 Note”) to its former California landlord. Due to the short-term nature of the September 2024 Note, the Company concluded that its carrying value approximated its fair value as of the Closing on November 14, 2024. The September 2024 Note bears no interest and is <span id="xdx_906_eus-gaap--DebtInstrumentPaymentTerms_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyFourNotePayableMember_z8oHGnILTls7" title="Payment terms">payable over twenty equal monthly instalments beginning on November 1, 2024, and expiring on June 1, 2026.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2026, and December 31, 2025, the outstanding balance on the September 2024 Note was less than $<span id="xdx_90E_eus-gaap--NotesPayableCurrent_iI_pn5n6_c20251231__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyFourNotePayableMember_zbiP2M0g28yg" title="Notes payable"><span id="xdx_907_eus-gaap--NotesPayableCurrent_iI_pn5n6_c20260331__us-gaap--DebtInstrumentAxis__custom--SeptemberTwoThousandTwentyFourNotePayableMember_zgtCjIVJRpQ" title="Notes payable">0.1</span></span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>April 2023 Convertible Notes</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2024, the Company assumed convertible promissory notes issued by Peak Bio in April 2023 in the principal amount of a total of $<span id="xdx_90E_eus-gaap--ConvertibleNotesPayableCurrent_iI_pn5n6_c20241130__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyThreeConvertibleNotesMember_zCzTUVjhg6h8" title="Principal amount">0.7</span> million (the “April 2023 Convertible Notes”). The April 2023 Convertible Notes permitted the holder to convert the outstanding principal and accrued interest at any time at a price of $<span id="xdx_907_eus-gaap--SharePrice_iI_pid_c20241130__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyThreeConvertibleNotesMember_zsu2lrwayBaf" title="Share price">81.60</span> per ADS (representing $<span id="xdx_90C_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20241130__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyThreeConvertibleNotesMember_zBN5hd83AhKh" title="Conversion price per share">0.00102</span> per underlying Ordinary Share of the Company). Due to the short-term nature of the April 2023 Convertible Notes, the Company concluded that its carrying value approximated its fair value as of the Closing on November 14, 2024. The April 2023 Convertible Notes were originally due on October 31, 2024, and bore interest at a default rate of <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20241130__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyThreeConvertibleNotesMember_zWMlJy2C9Pb4" title="Interest rate">10</span>% per annum.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluated the embedded conversion and other features within the April 2023 Convertible Notes to determine whether any of the embedded features should be bifurcated from the host instrument and accounted for as a derivative at fair value. Based on management’s evaluation, the Company determined that the April 2023 Convertible Notes were not issued at a substantial premium and none of the embedded features were required to be bifurcated and accounted for separately.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 19, 2025, the Company entered into a letter agreement (the “April 2023 Convertible Notes and Warrants Amendment”) with the holders of the April 2023 Convertible Notes to (i) extend the maturity date of the April 2023 Convertible Notes to August 31, 2026, (ii) amend the conversion price of the April 2023 Convertible Notes to $<span id="xdx_90A_eus-gaap--SharePrice_iI_pid_c20250919__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyThreeConvertibleNotesAndWarrantsAmendmentMember__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember_zDpvcKe2lnqi">32.40</span> per ADS (representing $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20250919__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyThreeConvertibleNotesAndWarrantsAmendmentMember__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember_za4sqKVhtyK7">0.000405</span> per underlying Ordinary Share) and permit the holders of the April 2023 Convertible Notes to voluntarily convert, in whole or in part, the outstanding principal and accrued but unpaid interest on the April 2023 Convertible Notes into ADSs at any time, (iii) extend the expiration date of warrants held by the April 2023 Convertible Note holders (“April 2023 Peak Bio Convertible Noteholder Warrants”) from April 28, 2028 to August 31, 2030, and (iv) amend the exercise price of the April 2023 Peak Bio Convertible Noteholder Warrants to $<span id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20250919__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyThreePeakBioConvertibleNoteholderWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember_zUB2A9xojLdi">32.40</span> per ADS (representing $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20250919__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyThreePeakBioConvertibleNoteholderWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--LetterAgreementMember_zQgWhcJNXJG2">0.000405</span> per underlying Ordinary Share).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounted for April 2023 Convertible Notes and Warrants Amendment as a debt extinguishment in accordance with ASC 470. As the present value of the future cash flows was substantially different than the net carrying value of the original debt, a loss on debt extinguishment of less than $<span id="xdx_90D_eus-gaap--DebtConversionOriginalDebtAmount1_pn5n6_c20250919__20250919__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyThreeConvertibleNotesAndWarrantsAmendmentMember_zuBbT67uK61" title="Debt conversion original debt">0.1</span> million was recognized during the three months ended September 30, 2025. The discount of less than $<span id="xdx_908_eus-gaap--InterestExpenseDebtExcludingAmortization_pn5n6_c20250919__20250919__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyThreeConvertibleNotesAndWarrantsAmendmentMember_zZnaSsqPDhvj" title="Amortization of interest expense">0.1</span> million is being amortized as interest expense over the term of the convertible notes using the effective interest method.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2024, in connection with the acquisition of Peak Bio, the April 2023 Peak Bio Convertible Noteholder Warrants were accounted for as a liability, as the April 2023 Peak Bio Convertible Noteholder Warrants were not considered indexed to the Company’s own stock in the manner contemplated by ASC 815-40-15, <i>Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity’s Own Stock</i>. Following the April 2023 Convertible Notes and Warrants Amendment on September 19, 2025, the Company determined that the amended April 2023 Peak Bio Convertible Noteholder Warrants for the issuance of <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250919__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyThreePeakBioConvertibleNoteholderWarrantsMember_zHyKiknqlg33" title="Number of warrants">8,560</span> ADSs (equivalent to <span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_pid_c20250919__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyThreePeakBioConvertibleNoteholderWarrantsMember_zFw7vBhMYCNc" title="Ordinary shares issued">684,840,000</span> Ordinary Shares) met the requirements to be considered indexed to the Company’s own stock and therefore were reclassified to equity. The fair value of the warrant liability, immediately prior to the modification, was $<span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_pid_c20250919__20250919__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyThreePeakBioConvertibleNoteholderWarrantsMember_zpcyU7NGZbic" title="Fair value of warrants">109,700</span> at the reclassification date. The Company determined the fair value of the April 2023 Peak Bio Convertible Noteholder Warrants after the modification, using a Black Scholes Option Pricing Model was $<span id="xdx_903_eus-gaap--AdditionalCollateralAggregateFairValue_iI_c20241130_zTXM5zRBMGk3" title="Aggregate fair value">191,800</span> based on a stock price of $<span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241130__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zV471VMUisN8" title="Stock price">0.81</span>, expected volatility of <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241130__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zRTGJYOPwjue" title="Expected volatility">86</span>%, a risk-free rate of <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20241130__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z1DcOxDGLYyb" title="Risk-free rate">3.68</span>% and an expected term of <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dtY_uPure_c20241130__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zhTieRvyQYmg" title="Expected term">5</span> years. The change in fair value of $<span id="xdx_90B_eus-gaap--FairValueAdjustmentOfWarrants_c20241101__20241130_zKAAu5LVrFHa" title="Change in fair value of warrants">82,100</span> was recognized as additional paid in capital during the three months ended September 30, 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized interest expense, including amortization of the discount of less than $<span id="xdx_902_eus-gaap--InterestExpenseDebt_pn5n6_c20250101__20250331__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyThreeConvertibleNoteMember_zUsWwyIeySqa" title="Interest expenses"><span id="xdx_90E_eus-gaap--InterestExpenseDebt_pn5n6_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyThreeConvertibleNoteMember_zXvCLFAfAAec" title="Interest expenses">0.1</span></span> million, in each of the three months ended March 31, 2026, and 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2026, and December 31, 2025, accrued interest on the April 2023 Convertible Notes of less than $<span id="xdx_904_eus-gaap--InterestPayableCurrent_iI_pn5n6_c20260331__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyThreeConvertibleNoteMember_zkFPQUIvpJN9" title="Accrued interest"><span id="xdx_90F_eus-gaap--InterestPayableCurrent_iI_pn5n6_c20251231__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyThreeConvertibleNoteMember_zQzUO848Dxq7" title="Accrued interest">0.1</span></span> million are presented within accrued expenses in the Company’s condensed unaudited consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_89C_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zv2gqJMzje9h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses consisted of the following as of March 31, 2026, and December 31, 2025 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zmnXoqitY3G2" style="display: none">Summary of Accrued Expenses</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_498_20260331_zbyklydjme" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" id="xdx_491_20251231_zuaZcx9CcqR9" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_408_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn3n3_maALCzd48_zrPM8cU5W8dl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Employee compensation and benefits</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">888</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">780</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--AccruedExternalResearchAndDevelopmentExpenses_iI_pn3n3_maALCzd48_zngB5zZefxkb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">External research and development expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,043</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">299</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALCzd48_zZf9cED1dJQ" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Professional and consulting fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">892</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">814</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCzd48_zhxqVY3bVgEe" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">505</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">449</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCzd48_zyCm4NCVOGuj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total accrued expenses</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,328</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,342</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 888000 780000 1043000 299000 892000 814000 505000 449000 3328000 2342000 300000 payable over twenty equal monthly instalments beginning on November 1, 2024, and expiring on June 1, 2026. 100000 100000 700000 81.60 0.00102 0.10 32.40 0.000405 32.40 0.000405 100000 100000 8560 684840000 109700 191800 0.81 86 3.68 5 82100 100000 100000 100000 100000 <p id="xdx_809_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zgKARuR8HLOh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 6. <span id="xdx_829_z1wwZSEhbcs6">Shareholders’ Equity</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Ordinary Shares</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2026, and December 31, 2025, the Company was authorized to issue up to <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20260331_zXKTZ3DHEXO6" title="Number of shares authorized"><span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20251231_zG7yBT16TUp3" title="Number of shares authorized">761,963,201,733</span></span> ordinary shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently, each ADS represents <span id="xdx_901_ecustom--NumberOfOrdinarySharesRepresentingOneAmericanDepositaryShare_iI_pid_c20260331__us-gaap--StatementClassOfStockAxis__dei--AdrMember__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesMember_zsgvdMeWd5z1" title="Number of ordinary shares representing one ADS">80,000</span> ordinary shares (the “ADS Ratio”). All ADS and per ADS amounts in the accompanying condensed consolidated financial statements reflect the ADS Ratio.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>White Lion Ordinary Share Purchase and Registration Rights Agreements</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 29, 2025, the Company entered into an Ordinary Share Purchase Agreement (the “ELOC Purchase Agreement”) and a Registration Rights Agreement (the “White Lion RRA”) with White Lion Capital, LLC, a Delaware limited liability company (“White Lion”). Pursuant to the ELOC Purchase Agreement, the Company had the right, but not the obligation, to require White Lion to purchase, from time to time, up to $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20250829__20250829__us-gaap--TypeOfArrangementAxis__custom--ELOCPurchaseAgreementMember__dei--LegalEntityAxis__custom--WhiteLionCapitalLLCMember_zwDmSds3IGv9" title="Gross proceeds from issuance of ordinary shares">25,000,000</span> in aggregate gross purchase price of newly issued Ordinary Shares, which may be exchanged for ADSs, subject to certain limitations and conditions set forth in the ELOC Purchase Agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company does not have a right to commence any sales of Ordinary Shares to White Lion under the ELOC Purchase Agreement until all conditions to the Company’s right to commence sales, as set forth in the ELOC Purchase Agreement, have been satisfied, including that a registration statement covering the resale of such shares is declared effective by the SEC and the final form of prospectus is filed with the SEC. Over the period ending on the earlier of (i) the date on which the Purchaser shall have purchased Ordinary Shares pursuant to the ELOC Purchase Agreement for an aggregate purchase price equal to the Commitment Amount or (ii) August 29, 2028 (the “Commitment Period”), subject to the conditions of the ELOC Purchase Agreement, the Company will control the timing and amount of any sales of Ordinary Shares to the Purchaser. Actual sales of Ordinary Shares to the Purchaser under the ELOC Purchase Agreement will depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the ADSs, and determinations made by the Company as to appropriate levels and sources of funding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The purchase price of the Ordinary Shares that the Company elects to sell to the Purchaser pursuant to the ELOC Purchase Agreement will be determined based on the type of Purchase Notice issued, as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rapid Purchase Option 1: The lowest traded price of the ADSs on the notice date.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rapid Purchase Option 2: <span id="xdx_902_ecustom--TradingPricePercentage_iI_pid_dp_uPure_c20250829_zRn9doCDTHP5" title="Trading percentage">97</span>% of the lowest traded price of the ADSs during the two hours following the Purchaser’s confirmed receipt of the notice.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rapid Purchase Option 3: The lowest of (i) the opening price of the ADSs on the notice date, (ii) the closing price of the ADSs on the prior business day, or (iii) the volume-weighted average price (VWAP) on the notice date, with a <span id="xdx_907_ecustom--TradingPriceDiscountPercentage_iI_pid_dp_uPure_c20250829_z91Nx0lULYta" title="Trading price discount percentage">20</span>% discount if the trading price is below the opening price.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">VWAP Purchase: <span id="xdx_903_ecustom--TradingPricePercentage_iI_pid_dp_uPure_c20250829_zECUFFyStzUd" title="Trading percentage">97</span>% of the lowest daily VWAP during a two-day valuation period for the first $<span id="xdx_907_ecustom--VolumeWeightedAveragePrice_pid_c20250829__20250829_z8ZY7WyZJ0T2" title="Volume weighted average price">12,500,000</span> of closings, and <span id="xdx_901_ecustom--TradingPercentageThereafter_iI_pid_dp_uPure_c20250829_zxWyHn6HnPzl" title="Trading percentage, thereafter">98</span>% thereafter.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In no event may the Company issue to the Purchaser under the ELOC Purchase Agreement more than <span id="xdx_907_eus-gaap--SharesIssued_iI_pid_c20250829__us-gaap--TypeOfArrangementAxis__custom--ELOCPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjUxN1pt6bxc" title="Ordinary shares issued">13,039,369,358</span> Ordinary Shares (the “Exchange Cap”), which equals <span id="xdx_904_eus-gaap--DerivativeExchangeRateCap1_iI_pid_dp_uPure_c20250829__us-gaap--TypeOfArrangementAxis__custom--ELOCPurchaseAgreementMember_zC2G7ZsBFDHh" title="Exchange cap rate">19.99</span>% of the Company’s outstanding Ordinary Shares as of the Execution Date, unless the Company obtains shareholder approval to issue shares in excess of the Exchange Cap or the average price paid for all Ordinary Shares issued under the agreement is equal to or greater than the Minimum Price (as defined in the ELOC Purchase Agreement). In any event, the ELOC Purchase Agreement provides that the Company may not issue or sell any Ordinary Shares if such issuance or sale would breach any applicable Nasdaq rules.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The ELOC Purchase Agreement prohibits the Company from directing the Purchaser to purchase any Ordinary Shares if those shares, when aggregated with all other Ordinary Shares then beneficially owned by the Purchaser (as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended), would result in the Purchaser beneficially owning more than <span id="xdx_90E_ecustom--BeneficialOwnershipLimitationPercentage_iI_pid_dp_uPure_c20250829__us-gaap--TypeOfArrangementAxis__custom--ELOCPurchaseAgreementMember_zlN1FpK6vX1f" title="Beneficial ownership limitation">4.99</span>% of the outstanding Ordinary Shares (the “Beneficial Ownership Limitation”), which may be increased to <span id="xdx_909_ecustom--BeneficialOwnershipLimitationPercentageIncrease_iI_pid_dp_uPure_c20250829__us-gaap--TypeOfArrangementAxis__custom--ELOCPurchaseAgreementMember_zrqANOLQHk51" title="Beneficial ownership limitation increased">9.99</span>% at the Purchaser’s discretion upon 61 days’ prior written notice.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--SignificantPurchaseCommitmentDescription_c20250829__20250829__us-gaap--TypeOfArrangementAxis__custom--ELOCPurchaseAgreementMember_zEtJ16W762n3" title="Purchase commitment, description">As consideration for the Purchaser’s execution of the ELOC Purchase Agreement, the Company will pay a document preparation fee of $<span id="xdx_905_eus-gaap--DebtInstrumentFeeAmount_iI_c20250829__us-gaap--TypeOfArrangementAxis__custom--ELOCPurchaseAgreementMember_zW6bm2OvFKuj" title="Document fee">15,000</span>, to be deducted from the proceeds related to the first Purchase Notice, and cash commitment fees of $37,500 when aggregate Purchase Notices exceed $500,000 and $87,500 (or $125,000 if $1,000,000 is reached first) when aggregate Purchase Notices exceed $1,000,000. Additionally, if the Company fails to close at least $625,000 in purchases by the 180th day after the Registration Statement’s effective date, the Company will issue ADSs, represented by Ordinary Shares, equivalent to $75,000 divided by the lowest traded ADS price during a 10-day period preceding that date (the “Commitment Shares”).</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrently with the ELOC Purchase Agreement, the Company and the Purchaser entered into a Registration Rights Agreement, dated August 29, 2025 (the “Registration Rights Agreement”), pursuant to which the Company agreed to file a registration statement on Form S-1 (or any successor form) with the SEC within thirty (30) calendar days following August 29, 2025, to register the resale of the maximum number of Registrable Securities (including the Ordinary Shares, Commitment Shares, and ADSs representing such shares) permitted by applicable SEC rules.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The ELOC Purchase Agreement was accounted for as a standby equity purchase agreement under ASC 815 as it includes an embedded put option and an embedded forward option. The put option is recognized on inception, and the forward option is recognized upon issuance of notice for the sale of the Company’s Common Stock. The fair value of the derivative liability related to the embedded put option (“White Lion Derivative Liability) was $<span id="xdx_902_eus-gaap--DerivativeLiabilityFairValueOfCollateral_iI_c20250829__us-gaap--TypeOfArrangementAxis__custom--ELOCPurchaseAgreementMember_zaROQxYhgU1k">100,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at the inception of the agreement. The fair value of the White Lion Derivative Liability was determined using a Monte Carlo simulation based on the projected stock price of $<span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20250829__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--TypeOfArrangementAxis__custom--ELOCPurchaseAgreementMember_zzvoGx3T7P42">0.76</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, expected volatility of <span id="xdx_902_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20250829__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--TypeOfArrangementAxis__custom--ELOCPurchaseAgreementMember_zEbKWtXAiGCd">97</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, risk-free rate of <span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20250829__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--TypeOfArrangementAxis__custom--ELOCPurchaseAgreementMember_z6t0nON1vrv5">3.52</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% and discounted at <span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20250829__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember__us-gaap--TypeOfArrangementAxis__custom--ELOCPurchaseAgreementMember_z01XJoivhq73">71.3</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% for the probability of the Company timely filing all SEC documents and meeting the NASDAQ listing requirements. </span>At March 31, 2026, the White Lion Derivative Liability was remeasured and had no value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2026, the Company had no outstanding purchase notices issued to White Lion.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>December 2025 Registered Direct Offering</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2025, the Company closed a registered direct offering (the “December 2025 Registered Direct Offering”) with institutional and non-institutional investors providing for the issuance and sale <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20251201__20251231__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z6YGs7yIfJ7f" title="Aggregate ADSs issued">19,057,418,000</span> ordinary shares of the Company (<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20251201__20251231__us-gaap--StatementEquityComponentsAxis__custom--OrdinarySharesMember_zE32tcYrhNXi" title="Aggregate ADSs issued">238,217</span> ADSs) and series G warrants (“Series G Warrants”) to purchase up to <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsMember_znWJKXsDMdC4" title="Warrants issued to purchase ADS">19,057,418,000</span> ordinary shares (<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20251231__us-gaap--StatementClassOfStockAxis__custom--ADSMember__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantsMember_zzCcPNZycHwj" title="Warrants issued to purchase ADS">238,217</span> ADSs). The combined purchase price per each ADS and accompanying Series G was $<span id="xdx_901_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantMember_zbilHkgIbXG9" title="Unit price">15.53</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Concurrent with the closing of the December 2025 Registered Direct Offering, the Company entered into a side letter with one non-institutional investor pursuant to which the Company agreed to issue <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20251231_zyIzGxdZUV98" title="Warrants issued">1,030,130,000</span> ordinary shares (<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20251231__us-gaap--StatementClassOfStockAxis__custom--ADSMember_zfS4ww8uclPd" title="Warrants issued">12,876</span> ADSs) and Series G Warrants to purchase <span id="xdx_90A_eus-gaap--CommonStockDiscountOnShares_iI_pid_c20251231_zXClKdKiKrJh" title="Common stock shares">1,030,130,000</span> ordinary shares (<span id="xdx_90B_eus-gaap--CommonStockDiscountOnShares_iI_pid_c20251231__us-gaap--StatementClassOfStockAxis__custom--ADSMember_z8vaegHUMCIg" title="Common stock shares">12,876</span> ADSs), not included in the total closing amount above, upon receipt of subscription amount of approximately $<span id="xdx_909_ecustom--SubscriptionAmount_pn5n6_c20251201__20251231_zYsfkmWp1rle" title="Subscription amount">0.2</span> million, which such subscription amount was received on January 15, 2026. The closing of this issuance occurred on January 30, 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Series G Warrants are exercisable at a price of $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20260302__us-gaap--ClassOfWarrantOrRightAxis__custom--SeriesGWarrantMember_zx2shxBxk3z9" title="Unit price">15.53</span> per ADS. The Series G Warrants became exercisable on March 2, 2026, and have a 5-year term. The Company determined that the Series G Warrants met all of the criteria for equity classification. Accordingly, each of the Series G Warrants issued on the January 30, 2026 closing was recorded as a component of additional paid-in capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net proceeds from the second closing of the December 2025 Registered Direct Offering was approximately $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn5n6_c20260101__20260331__us-gaap--DebtInstrumentAxis__custom--TwentyThousandTwentyFiveRegisteredDirectOfferingMember_z39Hyh5JvVFi" title="Aggregate gross proceeds">0.2</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrants</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with various previous financing transactions, the Company has issued warrants to purchase the Company’s ordinary shares represented by ADSs. The Company accounts for such warrants as equity instruments or liabilities, depending on the specific terms of the warrant agreement.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zuZNGoKYiol4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the Company’s outstanding warrants as of March 31, 2026, and December 31, 2025:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_zG5ZfhUbwFE" style="display: none">Schedule of Summarizes the Outstanding Warrants</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Warrant ADSs</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Weighted-</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Expiration Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Equity-classified Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left">December 2025 Investor Prefunded Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyFiveInvestorPrefundedWarrantMember_zqRHHFqYTx6g" style="width: 11%; text-align: right" title="Number of warrants ADSs">301,653</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyFiveInvestorPrefundedWarrantMember_zf1ywcMrQYi8" style="width: 11%; text-align: right" title="Number of warrants ADSs">301,653</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyFiveInvestorPrefundedWarrantMember_zGBXVJRMZI84" style="width: 11%; text-align: right" title="Weighted Average Exercise Price"><span style="-sec-ix-hidden: xdx2ixbrl0672">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 13%; text-align: center">None</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">April 2025 Investor Prefunded Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandAndTwentyFiveInvestorPrefundedWarrantsMember_zRJfAwxbpQyi" style="text-align: right" title="Number of warrants ADSs">41,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandAndTwentyFiveInvestorPrefundedWarrantsMember_zwVxvOBW7Te" style="text-align: right" title="Number of warrants ADSs">41,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandAndTwentyFiveInvestorPrefundedWarrantsMember_zKd3RpzYGfe1" style="text-align: right" title="Weighted Average Exercise Price">8.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">None</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">October 2023 Investor Prefunded Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--OctoberTwoThousandAndTwentyThreeInvestorPrefundedMember_zTsPbmqCLaa5" style="text-align: right" title="Number of warrants ADSs">1,209</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--OctoberTwoThousandAndTwentyThreeInvestorPrefundedMember_zcZgMkCV0ay7" style="text-align: right" title="Number of warrants ADSs">1,209</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--OctoberTwoThousandAndTwentyThreeInvestorPrefundedMember_z8ibpzJIPIwk" style="text-align: right" title="Weighted-Average Exercise Price">8.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">None</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">December 2025 Series G Investor Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyFiveSeriesGInvestorWarrantsMember_z8m2ipR3Iww1" style="text-align: right" title="Number of warrants ADSs">315,177</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyFiveSeriesGInvestorWarrantsMember_zZV5rVrqsan6" style="text-align: right" title="Number of warrants ADSs">302,301</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyFiveSeriesGInvestorWarrantsMember_zHarHpETEIn9" style="text-align: right" title="Weighted-Average Exercise Price">15.53</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">3/2/2031</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">December 2025 Note Exchange Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyFiveNoteWarrantsMember_zjoIYwMCijce" style="text-align: right" title="Number of warrants ADSs">237,564</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyFiveNoteWarrantsMember_zJXUWch2Hgv2" style="text-align: right" title="Number of warrants ADSs">237,564</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyFiveNoteWarrantsMember_zV7iAVp1LNe3" style="text-align: right" title="Weighted-Average Exercise Price">16.16</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">3/2/2031</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">December 2025 Placement Agent Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyFivePlacementAgentWarrantsMember_z3bemIvtQHc7" style="text-align: right" title="Number of warrants ADSs">12,604</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyFivePlacementAgentWarrantsMember_za2gUzz3mBV7" style="text-align: right" title="Number of warrants ADSs">12,604</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyFivePlacementAgentWarrantsMember_zdvdJO68NEEl" style="text-align: right" title="Weighted-Average Exercise Price">19.42</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">12/16/2030</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">April 2023 Peak Bio Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreePeakBioWarrantsMember_zTd61rH3pxob" style="text-align: right" title="Number of warrants ADSs">8,559</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreePeakBioWarrantsMember_zwbMw1Lverpk" style="text-align: right" title="Number of warrants ADSs">8,559</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreePeakBioWarrantsMember_z1OXkjA9yHye" style="text-align: right" title="Weighted-Average Exercise Price">32.40</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">8/30/2030</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">March 2025 Series A Investor Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandAndTwentyFiveSeriesAInvestorWarrantsMember_z701WyTJ8amc" style="text-align: right" title="Number of warrants ADSs"><span style="-sec-ix-hidden: xdx2ixbrl0710">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandAndTwentyFiveSeriesAInvestorWarrantsMember_zL7EOvXDDdW7" style="text-align: right" title="Number of warrants ADSs">8,861</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandAndTwentyFiveSeriesAInvestorWarrantsMember_zM7UoM3QoE94" style="text-align: right" title="Weighted-Average Exercise Price">34.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">3/6/2026</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>March 2025 Investor Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandAndTwentyFiveInvestorWarrantsMember_zxtmWnpWZBV5" style="text-align: right" title="Number of warrants ADSs">105,285</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandAndTwentyFiveInvestorWarrantsMember_ztV87pS3sdQ8" style="text-align: right" title="Number of warrants ADSs">105,285</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandAndTwentyFiveInvestorWarrantsMember_zbPUFleNyxGe" style="text-align: right" title="Weighted-Average Exercise Price">34.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">3/6/2030</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">April 2025 Series A Investor Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandAndTwentyFiveSeriesAInvestorWarrantsMember_ztv0HVYatCq9" style="text-align: right" title="Number of warrants ADSs">28,036</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandAndTwentyFiveSeriesAInvestorWarrantsMember_zRPP8TKtIxEk" style="text-align: right" title="Number of warrants ADSs">28,036</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandAndTwentyFiveSeriesAInvestorWarrantsMember_z3S9G34ztm1j" style="text-align: right" title="Weighted-Average Exercise Price">34.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">4/25/2026</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>April 2025 Investor Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandAndTwentyFiveInvestorWarrantsMember_zMCASQBJO4L3" style="text-align: right" title="Number of warrants ADSs">232,258</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandAndTwentyFiveInvestorWarrantsMember_zJZkkB5racEk" style="text-align: right" title="Number of warrants ADSs">232,258</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandAndTwentyFiveInvestorWarrantsMember_zUz7Dpm8dwK9" style="text-align: right" title="Weighted-Average Exercise Price">34.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">4/25/2030</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">October 2025 Series E Investor Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--OctoberTwoThousandAndTwentyFiveSeriesEInvestorWarrantsMember_zOvsHbdubkDf" style="text-align: right" title="Number of warrants ADSs">78,124</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--OctoberTwoThousandAndTwentyFiveSeriesEInvestorWarrantsMember_zU9HVVdZ1UW5" style="text-align: right" title="Number of warrants ADSs">78,124</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--OctoberTwoThousandAndTwentyFiveSeriesEInvestorWarrantsMember_z0OPSH0dj2Pe" style="text-align: right" title="Weighted-Average Exercise Price">39.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">12/15/2030</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">October 2025 Series F Investor Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--OctoberTwoThousandAndTwentyFiveSeriesFInvestorWarrantsMember_zY80iTzQT2Ia" style="text-align: right" title="Number of warrants ADSs">78,124</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--OctoberTwoThousandAndTwentyFiveSeriesFInvestorWarrantsMember_zeZeNqjIlHoi" style="text-align: right" title="Number of warrants ADSs">78,124</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--OctoberTwoThousandAndTwentyFiveSeriesFInvestorWarrantsMember_zQthBqgf3JYj" style="text-align: right" title="Weighted-Average Exercise Price">39.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">6/15/2028</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">October 2025 Placement Agent Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--OctoberTwoThousandAndTwentyFivePlacementAgentWarrantsMember_zaLRo6cIttme" style="text-align: right" title="Number of warrants ADSs">3,123</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--OctoberTwoThousandAndTwentyFivePlacementAgentWarrantsMember_zlQGRN0myZXk" style="text-align: right" title="Number of warrants ADSs">3,123</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--OctoberTwoThousandAndTwentyFivePlacementAgentWarrantsMember_zdTUzaQ2GwS9" style="text-align: right" title="Weighted-Average Exercise Price">40.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">10/14/2030</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>May 2024 Investor Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandAndTwentyFourInvestorWarrantsMember_zERYpZafqtUj" style="text-align: right" title="Number of warrants ADSs">100,739</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandAndTwentyFourInvestorWarrantsMember_zIptP230zHK1" style="text-align: right" title="Number of warrants ADSs">100,739</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandAndTwentyFourInvestorWarrantsMember_zLyhKWZIj7la" style="text-align: right" title="Weighted-Average Exercise Price">70.79</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">May-Jun 2027</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">March 2024 Placement Agent Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandAndTwentyFourPlacementAgentWarrantsMember_zWHCiuvo926e" style="text-align: right" title="Number of warrants ADSs">3,298</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandAndTwentyFourPlacementAgentWarrantsMember_z7tsWS4VfiPa" style="text-align: right" title="Number of warrants ADSs">3,298</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandAndTwentyFourPlacementAgentWarrantsMember_zM7bEGRawgcj" style="text-align: right" title="Weighted-Average Exercise Price">74.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">3/27/2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">May 2024 Placement Agent Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandAndTwentyFourPlacementAgentWarrantsMember_zdMrL2rH00sk" style="text-align: right" title="Number of warrants ADSs">8,056</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandAndTwentyFourPlacementAgentWarrantsMember_ziC3nm61LjJ7" style="text-align: right" title="Number of warrants ADSs">8,056</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandAndTwentyFourPlacementAgentWarrantsMember_zwVSn2woYLxk" style="text-align: right" title="Weighted-Average Exercise Price">75.40</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">5/31/2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>November 2024 Investor Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandAndTwentyFourInvestorWarrantsMember_zCIOkqmJgU6g" style="text-align: right" title="Number of warrants ADSs">42,832</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandAndTwentyFourInvestorWarrantsMember_zpBPFLy0slo5" style="text-align: right" title="Number of warrants ADSs">42,832</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandAndTwentyFourInvestorWarrantsMember_zuc8IDR7bSL2" style="text-align: right" title="Weighted-Average Exercise Price">90.40</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">Dec 2027-Jun 2028</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">October 2023 Placement Agent Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--OctoberTwoThousandAndTwentyThreePlacementAgentWarrantsMember_zhu6kABuW0S9" style="text-align: right" title="Number of warrants ADSs">1,058</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--OctoberTwoThousandAndTwentyThreePlacementAgentWarrantsMember_ztg9Gs5c35b8" style="text-align: right" title="Number of warrants ADSs">1,058</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--OctoberTwoThousandAndTwentyThreePlacementAgentWarrantsMember_z8mJdEwp6a5h" style="text-align: right" title="Weighted-Average Exercise Price">165.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">10/6/2028</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>March 2022 Investor Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandAndTwentyTwoInvestorWarrantsMember_zG62RPXsyq09" style="text-align: right" title="Number of warrants ADSs">4,637</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandAndTwentyTwoInvestorWarrantsMember_zT3VYCeprzol" style="text-align: right" title="Number of warrants ADSs">4,637</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandAndTwentyTwoInvestorWarrantsMember_zvWUk4WFQ0W2" style="text-align: right" title="Weighted-Average Exercise Price">1,120.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">3/10/2027</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">March 2022 Placement Agent Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandAndTwentyTwoPlacementAgentWarrantsMember_z5Jwy99BzDa9" style="text-align: right" title="Number of warrants ADSs">364</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandAndTwentyTwoPlacementAgentWarrantsMember_zQbTEuRLHRUd" style="text-align: right" title="Number of warrants ADSs">364</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandAndTwentyTwoPlacementAgentWarrantsMember_zitByblOPKC4" style="text-align: right" title="Weighted-Average Exercise Price">1,200.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">3/10/2027</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>December 2021 Investor Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyOneInvestorWarrantsMember_zL9l1vbkX6c" style="text-align: right" title="Number of warrants ADSs">2,681</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyOneInvestorWarrantsMember_zdXvaOQzITNl" style="text-align: right" title="Number of warrants ADSs">2,681</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyOneInvestorWarrantsMember_zrj4hLNgsYMe" style="text-align: right" title="Weighted-Average Exercise Price">1,320.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">1/4/2027</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">December 2021 Placement Agent <br/>Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyOnePlacementAgentWarrantsMember_zXUVwjgejREa" style="text-align: right" title="Number of warrants ADSs">208</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyOnePlacementAgentWarrantsMember_zkedkLQK2xm4" style="text-align: right" title="Number of warrants ADSs">208</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyOnePlacementAgentWarrantsMember_zUr1p0Sx3syb" style="text-align: right" title="Weighted-Average Exercise Price">1,400.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">12/29/2026</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">July 2021 Placement Agent Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--JulyTwoThousandAndTwentyOnePlacementAgentWarrantsMember_zaHnR7bNDvke" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants ADSs">487</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--JulyTwoThousandAndTwentyOnePlacementAgentWarrantsMember_zfM4tXoR2j14" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants ADSs">487</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--JulyTwoThousandAndTwentyOnePlacementAgentWarrantsMember_zCeCNYymPm03" style="padding-bottom: 1pt; text-align: right" title="Weighted-Average Exercise Price">1,856.00</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt">7/7/2026</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331_zpd6915dWtDl" style="text-align: right" title="Number of warrants ADSs">1,607,326</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231_zUEJdC5OmXO5" style="text-align: right" title="Number of warrants ADSs">1,603,311</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Liability-classified Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">April 2023 Peak Bio Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ClassOfWarrantOrRightOutstandingLiability_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreePeakBioWarrantsOneMember_zcR77ZtlZEId" style="text-align: right" title="Liability-classified Warrants">21,107</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ClassOfWarrantOrRightOutstandingLiability_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreePeakBioWarrantsOneMember_zJiZiY3EIQn8" style="text-align: right" title="Liability-classified Warrants">21,107</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreePeakBioWarrantsOneMember_zjK2zbFA3YN7" style="text-align: right" title="Weighted-Average Exercise Price">81.60</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">4/28/2028</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">September 2022 Series B Investor Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ClassOfWarrantOrRightOutstandingLiability_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--SeptemberTwoThousandTwentyTwoSeriesBInvestorWarrantsMember_zZ1vEhrqtOA2" style="text-align: right" title="Liability-classified Warrants">12,988</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ClassOfWarrantOrRightOutstandingLiability_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--SeptemberTwoThousandTwentyTwoSeriesBInvestorWarrantsMember_zWbHSm1gNuKg" style="text-align: right" title="Liability-classified Warrants">12,988</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--SeptemberTwoThousandTwentyTwoSeriesBInvestorWarrantsMember_zHytIN0u7an8" style="text-align: right" title="Weighted-Average Exercise Price">680.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">9/14/2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">November 2022 Peak Bio Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--ClassOfWarrantOrRightOutstandingLiability_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyTwoPeakBioWarrantsMember_zLFNvvFuXAq5" style="border-bottom: Black 1pt solid; text-align: right" title="Liability-classified Warrants">39,432</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_ecustom--ClassOfWarrantOrRightOutstandingLiability_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyTwoPeakBioWarrantsMember_zD48umDcqj2j" style="border-bottom: Black 1pt solid; text-align: right" title="Liability-classified Warrants">39,432</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyTwoPeakBioWarrantsMember_zSYar3wTBhHd" style="padding-bottom: 1pt; text-align: right" title="Weighted-Average Exercise Price">1,567.20</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt">11/1/2027</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_ecustom--LiabilityclassifiedWarrants_iI_pid_c20260331_zBYo0CpnjjX9" style="border-bottom: Black 1pt solid; text-align: right" title="Liability-classified Warrants">73,527</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_ecustom--LiabilityclassifiedWarrants_iI_pid_c20251231_zZRc5jRLh0xj" style="border-bottom: Black 1pt solid; text-align: right" title="Liability-classified Warrants">73,527</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total outstanding</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331_zlnFQNBAQlld" style="border-bottom: Black 2.5pt double; text-align: right" title="Total outstanding">1,680,853</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231_z98NdJIQhSAl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total outstanding">1,676,838</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td></tr> </table> <p id="xdx_8AE_z691fZSk5STi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_ecustom--ScheduleOfWarrantsActivityTextBlock_zD9siCmQPta5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the Company’s warrants activity for the three months ended March 31, 2026:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B6_zmDRVPzG8xS2" style="display: none">Schedule of Warrants Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; font-weight: bold">Outstanding at December 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zXGL8k3J77Yd" style="width: 16%; text-align: right" title="Number of Warrants Outstanding Beginning Balance">1,676,838</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--WeightedAverageExercisePriceOutstandingWarrants_iS_pid_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zhfaXXeSKEt8" style="width: 16%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning Balance">73.61</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zmR3ot2Smoi5" style="text-align: right" title="Number of Warrants, Issued">12,876</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--WeightedAverageExercisePriceIssuedWarrants_pid_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z7WBDferOJY4" style="text-align: right" title="Weighted-Average Exercise Price, Issued">15.53</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zsMzmA3V3iLe" style="text-align: right" title="Number of Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0852">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--WeightedAverageExercisePriceExercisedWarrants_pid_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zrywo4GiP2c6" style="text-align: right" title="Weighted-Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0854">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zKCZzcEU8xtb" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Expired">(8,861</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--WeightedAverageExercisePriceExpiredWarrants_pid_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zXxd2UWN9NG6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, Expired">34.80</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 2.5pt">Outstanding at March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z9e1lW6BMcga" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding Ending Balance">1,680,853</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--WeightedAverageExercisePriceOutstandingWarrants_iE_pid_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zS8ugeaUURpc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding, Ending Balance">73.36</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zz3sKE4zSa2l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> 761963201733 761963201733 80000 25000000 0.97 0.20 0.97 12500000 0.98 13039369358 0.1999 0.0499 0.0999 As consideration for the Purchaser’s execution of the ELOC Purchase Agreement, the Company will pay a document preparation fee of $15,000, to be deducted from the proceeds related to the first Purchase Notice, and cash commitment fees of $37,500 when aggregate Purchase Notices exceed $500,000 and $87,500 (or $125,000 if $1,000,000 is reached first) when aggregate Purchase Notices exceed $1,000,000. Additionally, if the Company fails to close at least $625,000 in purchases by the 180th day after the Registration Statement’s effective date, the Company will issue ADSs, represented by Ordinary Shares, equivalent to $75,000 divided by the lowest traded ADS price during a 10-day period preceding that date (the “Commitment Shares”). 15000 100000 0.76 97 3.52 71.3 19057418000 238217 19057418000 238217 15.53 1030130000 12876 1030130000 12876 200000 15.53 200000 <p id="xdx_89C_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zuZNGoKYiol4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the Company’s outstanding warrants as of March 31, 2026, and December 31, 2025:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_zG5ZfhUbwFE" style="display: none">Schedule of Summarizes the Outstanding Warrants</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Warrant ADSs</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="padding-bottom: 1pt; font-weight: bold; text-align: center">Weighted-</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Average</td><td style="font-weight: bold"> </td><td> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Expiration Date</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Equity-classified Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 40%; text-align: left">December 2025 Investor Prefunded Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyFiveInvestorPrefundedWarrantMember_zqRHHFqYTx6g" style="width: 11%; text-align: right" title="Number of warrants ADSs">301,653</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyFiveInvestorPrefundedWarrantMember_zf1ywcMrQYi8" style="width: 11%; text-align: right" title="Number of warrants ADSs">301,653</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyFiveInvestorPrefundedWarrantMember_zGBXVJRMZI84" style="width: 11%; text-align: right" title="Weighted Average Exercise Price"><span style="-sec-ix-hidden: xdx2ixbrl0672">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 13%; text-align: center">None</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">April 2025 Investor Prefunded Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandAndTwentyFiveInvestorPrefundedWarrantsMember_zRJfAwxbpQyi" style="text-align: right" title="Number of warrants ADSs">41,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandAndTwentyFiveInvestorPrefundedWarrantsMember_zwVxvOBW7Te" style="text-align: right" title="Number of warrants ADSs">41,250</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandAndTwentyFiveInvestorPrefundedWarrantsMember_zKd3RpzYGfe1" style="text-align: right" title="Weighted Average Exercise Price">8.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">None</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">October 2023 Investor Prefunded Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--OctoberTwoThousandAndTwentyThreeInvestorPrefundedMember_zTsPbmqCLaa5" style="text-align: right" title="Number of warrants ADSs">1,209</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--OctoberTwoThousandAndTwentyThreeInvestorPrefundedMember_zcZgMkCV0ay7" style="text-align: right" title="Number of warrants ADSs">1,209</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--OctoberTwoThousandAndTwentyThreeInvestorPrefundedMember_z8ibpzJIPIwk" style="text-align: right" title="Weighted-Average Exercise Price">8.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">None</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">December 2025 Series G Investor Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyFiveSeriesGInvestorWarrantsMember_z8m2ipR3Iww1" style="text-align: right" title="Number of warrants ADSs">315,177</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyFiveSeriesGInvestorWarrantsMember_zZV5rVrqsan6" style="text-align: right" title="Number of warrants ADSs">302,301</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyFiveSeriesGInvestorWarrantsMember_zHarHpETEIn9" style="text-align: right" title="Weighted-Average Exercise Price">15.53</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">3/2/2031</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">December 2025 Note Exchange Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyFiveNoteWarrantsMember_zjoIYwMCijce" style="text-align: right" title="Number of warrants ADSs">237,564</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyFiveNoteWarrantsMember_zJXUWch2Hgv2" style="text-align: right" title="Number of warrants ADSs">237,564</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyFiveNoteWarrantsMember_zV7iAVp1LNe3" style="text-align: right" title="Weighted-Average Exercise Price">16.16</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">3/2/2031</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">December 2025 Placement Agent Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyFivePlacementAgentWarrantsMember_z3bemIvtQHc7" style="text-align: right" title="Number of warrants ADSs">12,604</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyFivePlacementAgentWarrantsMember_za2gUzz3mBV7" style="text-align: right" title="Number of warrants ADSs">12,604</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyFivePlacementAgentWarrantsMember_zdvdJO68NEEl" style="text-align: right" title="Weighted-Average Exercise Price">19.42</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">12/16/2030</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">April 2023 Peak Bio Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreePeakBioWarrantsMember_zTd61rH3pxob" style="text-align: right" title="Number of warrants ADSs">8,559</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreePeakBioWarrantsMember_zwbMw1Lverpk" style="text-align: right" title="Number of warrants ADSs">8,559</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreePeakBioWarrantsMember_z1OXkjA9yHye" style="text-align: right" title="Weighted-Average Exercise Price">32.40</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">8/30/2030</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">March 2025 Series A Investor Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandAndTwentyFiveSeriesAInvestorWarrantsMember_z701WyTJ8amc" style="text-align: right" title="Number of warrants ADSs"><span style="-sec-ix-hidden: xdx2ixbrl0710">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandAndTwentyFiveSeriesAInvestorWarrantsMember_zL7EOvXDDdW7" style="text-align: right" title="Number of warrants ADSs">8,861</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandAndTwentyFiveSeriesAInvestorWarrantsMember_zM7UoM3QoE94" style="text-align: right" title="Weighted-Average Exercise Price">34.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">3/6/2026</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>March 2025 Investor Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandAndTwentyFiveInvestorWarrantsMember_zxtmWnpWZBV5" style="text-align: right" title="Number of warrants ADSs">105,285</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandAndTwentyFiveInvestorWarrantsMember_ztV87pS3sdQ8" style="text-align: right" title="Number of warrants ADSs">105,285</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandAndTwentyFiveInvestorWarrantsMember_zbPUFleNyxGe" style="text-align: right" title="Weighted-Average Exercise Price">34.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">3/6/2030</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">April 2025 Series A Investor Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandAndTwentyFiveSeriesAInvestorWarrantsMember_ztv0HVYatCq9" style="text-align: right" title="Number of warrants ADSs">28,036</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandAndTwentyFiveSeriesAInvestorWarrantsMember_zRPP8TKtIxEk" style="text-align: right" title="Number of warrants ADSs">28,036</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandAndTwentyFiveSeriesAInvestorWarrantsMember_z3S9G34ztm1j" style="text-align: right" title="Weighted-Average Exercise Price">34.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">4/25/2026</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>April 2025 Investor Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandAndTwentyFiveInvestorWarrantsMember_zMCASQBJO4L3" style="text-align: right" title="Number of warrants ADSs">232,258</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandAndTwentyFiveInvestorWarrantsMember_zJZkkB5racEk" style="text-align: right" title="Number of warrants ADSs">232,258</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandAndTwentyFiveInvestorWarrantsMember_zUz7Dpm8dwK9" style="text-align: right" title="Weighted-Average Exercise Price">34.80</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">4/25/2030</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">October 2025 Series E Investor Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--OctoberTwoThousandAndTwentyFiveSeriesEInvestorWarrantsMember_zOvsHbdubkDf" style="text-align: right" title="Number of warrants ADSs">78,124</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--OctoberTwoThousandAndTwentyFiveSeriesEInvestorWarrantsMember_zU9HVVdZ1UW5" style="text-align: right" title="Number of warrants ADSs">78,124</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--OctoberTwoThousandAndTwentyFiveSeriesEInvestorWarrantsMember_z0OPSH0dj2Pe" style="text-align: right" title="Weighted-Average Exercise Price">39.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">12/15/2030</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">October 2025 Series F Investor Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--OctoberTwoThousandAndTwentyFiveSeriesFInvestorWarrantsMember_zY80iTzQT2Ia" style="text-align: right" title="Number of warrants ADSs">78,124</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--OctoberTwoThousandAndTwentyFiveSeriesFInvestorWarrantsMember_zeZeNqjIlHoi" style="text-align: right" title="Number of warrants ADSs">78,124</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--OctoberTwoThousandAndTwentyFiveSeriesFInvestorWarrantsMember_zQthBqgf3JYj" style="text-align: right" title="Weighted-Average Exercise Price">39.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">6/15/2028</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">October 2025 Placement Agent Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--OctoberTwoThousandAndTwentyFivePlacementAgentWarrantsMember_zaLRo6cIttme" style="text-align: right" title="Number of warrants ADSs">3,123</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--OctoberTwoThousandAndTwentyFivePlacementAgentWarrantsMember_zlQGRN0myZXk" style="text-align: right" title="Number of warrants ADSs">3,123</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--OctoberTwoThousandAndTwentyFivePlacementAgentWarrantsMember_zdTUzaQ2GwS9" style="text-align: right" title="Weighted-Average Exercise Price">40.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">10/14/2030</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>May 2024 Investor Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandAndTwentyFourInvestorWarrantsMember_zERYpZafqtUj" style="text-align: right" title="Number of warrants ADSs">100,739</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandAndTwentyFourInvestorWarrantsMember_zIptP230zHK1" style="text-align: right" title="Number of warrants ADSs">100,739</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandAndTwentyFourInvestorWarrantsMember_zLyhKWZIj7la" style="text-align: right" title="Weighted-Average Exercise Price">70.79</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">May-Jun 2027</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">March 2024 Placement Agent Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandAndTwentyFourPlacementAgentWarrantsMember_zWHCiuvo926e" style="text-align: right" title="Number of warrants ADSs">3,298</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandAndTwentyFourPlacementAgentWarrantsMember_z7tsWS4VfiPa" style="text-align: right" title="Number of warrants ADSs">3,298</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandAndTwentyFourPlacementAgentWarrantsMember_zM7bEGRawgcj" style="text-align: right" title="Weighted-Average Exercise Price">74.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">3/27/2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">May 2024 Placement Agent Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandAndTwentyFourPlacementAgentWarrantsMember_zdMrL2rH00sk" style="text-align: right" title="Number of warrants ADSs">8,056</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandAndTwentyFourPlacementAgentWarrantsMember_ziC3nm61LjJ7" style="text-align: right" title="Number of warrants ADSs">8,056</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--MayTwoThousandAndTwentyFourPlacementAgentWarrantsMember_zwVSn2woYLxk" style="text-align: right" title="Weighted-Average Exercise Price">75.40</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">5/31/2029</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>November 2024 Investor Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandAndTwentyFourInvestorWarrantsMember_zCIOkqmJgU6g" style="text-align: right" title="Number of warrants ADSs">42,832</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandAndTwentyFourInvestorWarrantsMember_zpBPFLy0slo5" style="text-align: right" title="Number of warrants ADSs">42,832</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandAndTwentyFourInvestorWarrantsMember_zuc8IDR7bSL2" style="text-align: right" title="Weighted-Average Exercise Price">90.40</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">Dec 2027-Jun 2028</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">October 2023 Placement Agent Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--OctoberTwoThousandAndTwentyThreePlacementAgentWarrantsMember_zhu6kABuW0S9" style="text-align: right" title="Number of warrants ADSs">1,058</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--OctoberTwoThousandAndTwentyThreePlacementAgentWarrantsMember_ztg9Gs5c35b8" style="text-align: right" title="Number of warrants ADSs">1,058</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--OctoberTwoThousandAndTwentyThreePlacementAgentWarrantsMember_z8mJdEwp6a5h" style="text-align: right" title="Weighted-Average Exercise Price">165.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">10/6/2028</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>March 2022 Investor Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandAndTwentyTwoInvestorWarrantsMember_zG62RPXsyq09" style="text-align: right" title="Number of warrants ADSs">4,637</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandAndTwentyTwoInvestorWarrantsMember_zT3VYCeprzol" style="text-align: right" title="Number of warrants ADSs">4,637</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandAndTwentyTwoInvestorWarrantsMember_zvWUk4WFQ0W2" style="text-align: right" title="Weighted-Average Exercise Price">1,120.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">3/10/2027</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">March 2022 Placement Agent Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandAndTwentyTwoPlacementAgentWarrantsMember_z5Jwy99BzDa9" style="text-align: right" title="Number of warrants ADSs">364</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandAndTwentyTwoPlacementAgentWarrantsMember_zQbTEuRLHRUd" style="text-align: right" title="Number of warrants ADSs">364</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--MarchTwoThousandAndTwentyTwoPlacementAgentWarrantsMember_zitByblOPKC4" style="text-align: right" title="Weighted-Average Exercise Price">1,200.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">3/10/2027</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>December 2021 Investor Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyOneInvestorWarrantsMember_zL9l1vbkX6c" style="text-align: right" title="Number of warrants ADSs">2,681</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyOneInvestorWarrantsMember_zdXvaOQzITNl" style="text-align: right" title="Number of warrants ADSs">2,681</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyOneInvestorWarrantsMember_zrj4hLNgsYMe" style="text-align: right" title="Weighted-Average Exercise Price">1,320.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">1/4/2027</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">December 2021 Placement Agent <br/>Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyOnePlacementAgentWarrantsMember_zXUVwjgejREa" style="text-align: right" title="Number of warrants ADSs">208</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyOnePlacementAgentWarrantsMember_zkedkLQK2xm4" style="text-align: right" title="Number of warrants ADSs">208</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--DecemberTwoThousandAndTwentyOnePlacementAgentWarrantsMember_zUr1p0Sx3syb" style="text-align: right" title="Weighted-Average Exercise Price">1,400.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">12/29/2026</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">July 2021 Placement Agent Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--JulyTwoThousandAndTwentyOnePlacementAgentWarrantsMember_zaHnR7bNDvke" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants ADSs">487</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--JulyTwoThousandAndTwentyOnePlacementAgentWarrantsMember_zfM4tXoR2j14" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants ADSs">487</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--JulyTwoThousandAndTwentyOnePlacementAgentWarrantsMember_zCeCNYymPm03" style="padding-bottom: 1pt; text-align: right" title="Weighted-Average Exercise Price">1,856.00</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt">7/7/2026</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20260331_zpd6915dWtDl" style="text-align: right" title="Number of warrants ADSs">1,607,326</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ClassOfWarrantOrRightOutstandingEquity_iI_pid_c20251231_zUEJdC5OmXO5" style="text-align: right" title="Number of warrants ADSs">1,603,311</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Liability-classified Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">April 2023 Peak Bio Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--ClassOfWarrantOrRightOutstandingLiability_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreePeakBioWarrantsOneMember_zcR77ZtlZEId" style="text-align: right" title="Liability-classified Warrants">21,107</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_ecustom--ClassOfWarrantOrRightOutstandingLiability_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreePeakBioWarrantsOneMember_zJiZiY3EIQn8" style="text-align: right" title="Liability-classified Warrants">21,107</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--AprilTwoThousandTwentyThreePeakBioWarrantsOneMember_zjK2zbFA3YN7" style="text-align: right" title="Weighted-Average Exercise Price">81.60</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">4/28/2028</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">September 2022 Series B Investor Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--ClassOfWarrantOrRightOutstandingLiability_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--SeptemberTwoThousandTwentyTwoSeriesBInvestorWarrantsMember_zZ1vEhrqtOA2" style="text-align: right" title="Liability-classified Warrants">12,988</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_ecustom--ClassOfWarrantOrRightOutstandingLiability_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--SeptemberTwoThousandTwentyTwoSeriesBInvestorWarrantsMember_zWbHSm1gNuKg" style="text-align: right" title="Liability-classified Warrants">12,988</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--SeptemberTwoThousandTwentyTwoSeriesBInvestorWarrantsMember_zHytIN0u7an8" style="text-align: right" title="Weighted-Average Exercise Price">680.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center">9/14/2029</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">November 2022 Peak Bio Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_ecustom--ClassOfWarrantOrRightOutstandingLiability_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyTwoPeakBioWarrantsMember_zLFNvvFuXAq5" style="border-bottom: Black 1pt solid; text-align: right" title="Liability-classified Warrants">39,432</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_ecustom--ClassOfWarrantOrRightOutstandingLiability_iI_pid_c20251231__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyTwoPeakBioWarrantsMember_zD48umDcqj2j" style="border-bottom: Black 1pt solid; text-align: right" title="Liability-classified Warrants">39,432</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__custom--NovemberTwoThousandTwentyTwoPeakBioWarrantsMember_zSYar3wTBhHd" style="padding-bottom: 1pt; text-align: right" title="Weighted-Average Exercise Price">1,567.20</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt">11/1/2027</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_ecustom--LiabilityclassifiedWarrants_iI_pid_c20260331_zBYo0CpnjjX9" style="border-bottom: Black 1pt solid; text-align: right" title="Liability-classified Warrants">73,527</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_ecustom--LiabilityclassifiedWarrants_iI_pid_c20251231_zZRc5jRLh0xj" style="border-bottom: Black 1pt solid; text-align: right" title="Liability-classified Warrants">73,527</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: center; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total outstanding</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331_zlnFQNBAQlld" style="border-bottom: Black 2.5pt double; text-align: right" title="Total outstanding">1,680,853</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231_z98NdJIQhSAl" style="border-bottom: Black 2.5pt double; text-align: right" title="Total outstanding">1,676,838</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: center; padding-bottom: 2.5pt"> </td></tr> </table> 301653 301653 41250 41250 8.00 1209 1209 8.00 315177 302301 15.53 237564 237564 16.16 12604 12604 19.42 8559 8559 32.40 8861 34.80 105285 105285 34.80 28036 28036 34.80 232258 232258 34.80 78124 78124 39.20 78124 78124 39.20 3123 3123 40.00 100739 100739 70.79 3298 3298 74.00 8056 8056 75.40 42832 42832 90.40 1058 1058 165.20 4637 4637 1120.00 364 364 1200.00 2681 2681 1320.00 208 208 1400.00 487 487 1856.00 1607326 1603311 21107 21107 81.60 12988 12988 680.00 39432 39432 1567.20 73527 73527 1680853 1676838 <p id="xdx_898_ecustom--ScheduleOfWarrantsActivityTextBlock_zD9siCmQPta5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the Company’s warrants activity for the three months ended March 31, 2026:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B6_zmDRVPzG8xS2" style="display: none">Schedule of Warrants Activity</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Weighted-Average</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; font-weight: bold">Outstanding at December 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zXGL8k3J77Yd" style="width: 16%; text-align: right" title="Number of Warrants Outstanding Beginning Balance">1,676,838</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_ecustom--WeightedAverageExercisePriceOutstandingWarrants_iS_pid_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zhfaXXeSKEt8" style="width: 16%; text-align: right" title="Weighted Average Exercise Price Outstanding, Beginning Balance">73.61</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zmR3ot2Smoi5" style="text-align: right" title="Number of Warrants, Issued">12,876</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--WeightedAverageExercisePriceIssuedWarrants_pid_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z7WBDferOJY4" style="text-align: right" title="Weighted-Average Exercise Price, Issued">15.53</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_pid_di_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zsMzmA3V3iLe" style="text-align: right" title="Number of Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0852">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_ecustom--WeightedAverageExercisePriceExercisedWarrants_pid_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zrywo4GiP2c6" style="text-align: right" title="Weighted-Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0854">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_pid_di_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zKCZzcEU8xtb" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Expired">(8,861</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_ecustom--WeightedAverageExercisePriceExpiredWarrants_pid_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zXxd2UWN9NG6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, Expired">34.80</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 2.5pt">Outstanding at March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z9e1lW6BMcga" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants Outstanding Ending Balance">1,680,853</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_ecustom--WeightedAverageExercisePriceOutstandingWarrants_iE_pid_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zS8ugeaUURpc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding, Ending Balance">73.36</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1676838 73.61 12876 15.53 8861 34.80 1680853 73.36 <p id="xdx_801_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z4NqGqwWdMsa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 7. <span id="xdx_82D_zR6G3SAAS0Zj">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock Options</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z9BXSWRhsSFe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a summary of the Company’s stock option activity, with each ADS representing 80,000 Ordinary Shares, under the 2014 Equity Incentive Plan, 2023 Equity Incentive Plan and the Peak Bio 2022 Long Term Incentive Plan for the three months ended March 31, 2026:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B5_zJyEO31F2S19" style="display: none">Schedule of Stock Option Activity</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option ADSs</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual Life</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in years)</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; font-weight: bold">Outstanding at December 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_zlmV3eQfpE54" style="width: 12%; text-align: right" title="Number of shares, Options Outstanding">170,137</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_zZjtjok8Qrvf" style="width: 12%; text-align: right" title="Weighted average exercise price, Outstanding at beginning">109.65</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_zvQuNyg9oJvd" title="Weighted average remaining contractual life, Options outstanding">8.8</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_zcVKZR1Y2Qve" style="width: 12%; text-align: right" title="Aggregate intrinsic value, Options outstanding"><span style="-sec-ix-hidden: xdx2ixbrl0874">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_zJBE5E2AdWK8" style="text-align: right" title="Number of shares, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0876">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_zoVn1ht2bPk1" style="text-align: right" title="Weighted average exercise price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0878">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_zruXLgv3XkFb" style="text-align: right" title="Number of shares, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0880">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_zD6x52iOJHki" style="text-align: right" title="Weighted average exercise price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0882">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_zCLiRqxp6xTg" style="text-align: right" title="Number of shares, Forfeited">(8,750</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_zgZign9H6Ei2" style="text-align: right" title="Weighted average exercise price, Forfeited">47.66</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_zYQeSphYmwq" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, Expired">(6,891</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_zaQsiH3HLAe1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Expired">674.23</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 2.5pt">Outstanding at March 31, 2026 (1)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_fKDEp_zKhWTcDOHqqd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Options Outstanding">154,496</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_fKDEp_zVs5bHRa7Jfb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Outstanding at ending">87.97</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_fKDEp_zHERE58wmlo3" title="Weighted average remaining contractual life, Options outstanding">8.8</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_fKDEp_zXKGWswbDwJ5" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Options outstanding"><span style="-sec-ix-hidden: xdx2ixbrl0898">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 2.5pt">Exercisable at March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_z8TdT10Q8vYd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock options exercisable shares">88,604</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_zHVdsidFLfW6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Exercisable">108.48</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_zjAVZLTBkZKi" title="Weighted average remaining contractual term, Options exercisable">8.6</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_z58hAsYLIXy5" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Options exercisable"><span style="-sec-ix-hidden: xdx2ixbrl0906">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <div style="margin-top: 0pt; margin-left: 0.25in; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt"> </div></div> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F08_zVLWhAqO1gih" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F18_z2DQs1qwFSzd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes both vested stock options as well as unvested stock options for which the requisite service period has not been rendered but that are expected to vest based on achievement of a service condition.</span></td></tr></table> <p id="xdx_8A3_zMR0gLOjQAs7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48.95pt; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The aggregate intrinsic value of options is calculated as the difference between the exercise price of the options and the fair value of the Company’s ADSs for those options that had exercise prices lower than the fair value of the Company’s ordinary shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted-average grant-date fair value per ADS of options granted during each of the three months ended March 31, 2026 and 2025 was $<span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20260101__20260331_zV89dblk8wP8" title="Weighted average grant date">0</span> and $<span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_c20250101__20250331_zbj5NO1L8eRf" title="Weighted average grant date">46.48</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Option Valuation</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zMz0rTq57qAi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted-average assumptions that the Company used to determine the fair value of share options granted were as follows, presented on a weighted average basis:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B4_z7Xyn3TRYj8b" style="display: none">Schedule of Weighted-average Assumptions and Fair Value of Share Options Granted</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20260101__20260331_zOKraQZe5Zr6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20250101__20250331_zSG9Qhs3tsXe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_zQJhVdUwYHYd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Expected volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0915">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">95.7</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_401_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_zyhLyQg9iqTg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0918">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.0</td><td style="text-align: left">%</td></tr> <tr id="xdx_401_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_zzj1WLo6Ya2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0921">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0922">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250331_zHj6oFRQiWO1" title="Expected term (in years)">5.8</span></td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AC_zWsIqkcnO2Ha" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Restricted Stock Units</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The 2023 Plan provides for the award of RSUs. RSUs are granted to employees that are subject to time-based vesting conditions that lapse between one year and four years from date of grant, assuming continued employment. Compensation cost for time-based RSUs, which generally vest only on continued service, is recognized on a straight-line basis over the requisite service period based on the grant date fair value of the RSUs, which is derived from the Nasdaq closing price of the Company’s ADSs on the date of grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_z6lwblLlVlv4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the Company’s restricted stock activity for the three months ended March 31, 2026:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_zFJ2w5LPYXub" style="display: none">Schedule of RSU activity</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Time-based Awards</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of ADSs</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Grant Date </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; font-weight: bold">Nonvested shares at December 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkPKR2ysxp4d" style="width: 16%; text-align: right" title="Number of ADSs nonvested shares, balance">1,465</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z78B1yYlHaC2" style="width: 16%; text-align: right" title="Weighted average grant date fair value per share, Beginning">30.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXImnyhVhqza" style="text-align: right" title="Number of ADSs nonvested shares, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0932">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zuGEx2VDmXP1" style="text-align: right" title="Weighted average grant date fair value per share, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0934">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zW6Qy9ISY8Q7" style="text-align: right" title="Number of ADSs nonvested shares, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0936">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0hCWVhEnqv4" style="text-align: right" title="Weighted average grant date fair value per share, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0938">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 0pt">Vested</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zz1C9uuE4OE4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of ADSs nonvested shares, Vested">(1,465</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zu6JNttemwk7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value per share, Vested">30.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 2.5pt">Nonvested shares at March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zowR6MsxHPk9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of ADSs nonvested shares, balance"><span style="-sec-ix-hidden: xdx2ixbrl0944">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zSTOkYG9xaS2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value per share, Ending"><span style="-sec-ix-hidden: xdx2ixbrl0946">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A3_zLfZHCVvnSCg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2026, <span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnderlyingVestedInPeriod_iI_c20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7bFHaKIDBG3" title="Shares underlying vested">1,622</span> ADSs (<span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsUnderlyingVestedInPeriod_iI_c20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvlUyGpNmF2i" title="Shares underlying vested">129,792,000</span> ordinary shares) underlying vested time-based RSUs were pending issuance. The fair value of time-based RSUs that vested during the three months ended March 31, 2026 was less than $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_pn5n6_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zRX8oBNU4FVh" title="Fair value of time-based RSUs that vested">0.1</span> million. The Company had no activity in restricted stock awards for the three months ended March 31, 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Performance-Based Stock Options</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had previously awarded performance-based stock options (“PSOs”) for the purchase of an aggregate of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--PerformanceSharesMember_zlM6yIS8pni1" title="Aggregate of shares">9,375</span> ADSs of the Company outstanding to consultants. Vesting of PSOs granted to consultants were based upon attainment of certain research and licensing agreements and were subject to continuous service by the consultants. During the three months ended March 31, 2026, all PSOs expired or were forfeited and as a result, the Company has not recognized stock-based compensation expense associated with these PSOs. During the three months ended March 31, 2025, all outstanding PSOs were not probable of vesting and as a result, the Company did not recognize any stock-based compensation associated with these PSOs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Stock-Based Compensation Expense</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company classifies stock-based compensation expense in the condensed consolidated statements of operations and comprehensive loss in the same manner in which the award recipients’ payroll costs are classified or in which the award recipients’ service payments are classified. Total stock-based compensation expense attributable to share-based payments made to employees, consultants and directors included in operating expenses in the Company’s condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2026 and 2025, was as follows:</span></p> <p id="xdx_890_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zGohJIqgXzvj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B7_zLG69sn9tci1" style="display: none">Schedule of Stock-based Compensation Expense in Statements of Operations</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; display: none; font-weight: bold">($ in thousands)</td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20260101__20260331_z0kBF2WuZMl1" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2026</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20250101__20250331_zBGPQytOo4r" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">($ in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hsrt--ProductOrServiceAxis__custom--ResearchAndDevelopmentExpensesMember_zdljMyMrGkdb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Research and development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">19</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">191</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hsrt--ProductOrServiceAxis__custom--SellingGeneralAndAdministrativeExpenseMember_ziEVjSIO1GM3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">286</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">824</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_z8XUvmhQwsJ7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">305</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,015</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zOtG8QEYaA95" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2026, total unrecognized compensation cost related to unvested stock options was $<span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20260331__us-gaap--AwardTypeAxis__custom--UnvestedStockOptionMember_zORDbj1WUShi" title="Unrecognized compensation">3.2</span> million, which is expected to be recognized over a weighted average period of <span id="xdx_905_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20260101__20260331__us-gaap--AwardTypeAxis__custom--UnvestedStockOptionMember_zWL5dD794Nk9" title="Weighted average period">2.6</span> years. As of March 31, 2026, no unrecognized compensation cost remains related to time-based RSUs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z9BXSWRhsSFe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a summary of the Company’s stock option activity, with each ADS representing 80,000 Ordinary Shares, under the 2014 Equity Incentive Plan, 2023 Equity Incentive Plan and the Peak Bio 2022 Long Term Incentive Plan for the three months ended March 31, 2026:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B5_zJyEO31F2S19" style="display: none">Schedule of Stock Option Activity</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option ADSs</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractual Life</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(in years)</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggregate</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intrinsic </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Value</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; font-weight: bold">Outstanding at December 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_zlmV3eQfpE54" style="width: 12%; text-align: right" title="Number of shares, Options Outstanding">170,137</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_zZjtjok8Qrvf" style="width: 12%; text-align: right" title="Weighted average exercise price, Outstanding at beginning">109.65</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_zvQuNyg9oJvd" title="Weighted average remaining contractual life, Options outstanding">8.8</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_zcVKZR1Y2Qve" style="width: 12%; text-align: right" title="Aggregate intrinsic value, Options outstanding"><span style="-sec-ix-hidden: xdx2ixbrl0874">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_zJBE5E2AdWK8" style="text-align: right" title="Number of shares, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0876">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_zoVn1ht2bPk1" style="text-align: right" title="Weighted average exercise price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0878">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_zruXLgv3XkFb" style="text-align: right" title="Number of shares, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0880">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_zD6x52iOJHki" style="text-align: right" title="Weighted average exercise price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0882">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pid_di_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_zCLiRqxp6xTg" style="text-align: right" title="Number of shares, Forfeited">(8,750</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_zgZign9H6Ei2" style="text-align: right" title="Weighted average exercise price, Forfeited">47.66</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_zYQeSphYmwq" style="border-bottom: Black 1pt solid; text-align: right" title="Number of shares, Expired">(6,891</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_zaQsiH3HLAe1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted average exercise price, Expired">674.23</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 2.5pt">Outstanding at March 31, 2026 (1)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_fKDEp_zKhWTcDOHqqd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Options Outstanding">154,496</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_fKDEp_zVs5bHRa7Jfb" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Outstanding at ending">87.97</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_fKDEp_zHERE58wmlo3" title="Weighted average remaining contractual life, Options outstanding">8.8</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_fKDEp_zXKGWswbDwJ5" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Options outstanding"><span style="-sec-ix-hidden: xdx2ixbrl0898">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 2.5pt">Exercisable at March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_z8TdT10Q8vYd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of stock options exercisable shares">88,604</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_zHVdsidFLfW6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average exercise price, Exercisable">108.48</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_zjAVZLTBkZKi" title="Weighted average remaining contractual term, Options exercisable">8.6</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20260331__us-gaap--PlanNameAxis__custom--EquityIncentivePlan2014EquityIncentivePlan2023AndPeakBio2022LongTermIncentivePlanMember_z58hAsYLIXy5" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value, Options exercisable"><span style="-sec-ix-hidden: xdx2ixbrl0906">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <div style="margin-top: 0pt; margin-left: 0.25in; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1pt solid; font-size: 1pt"> </div></div> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F08_zVLWhAqO1gih" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F18_z2DQs1qwFSzd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes both vested stock options as well as unvested stock options for which the requisite service period has not been rendered but that are expected to vest based on achievement of a service condition.</span></td></tr></table> 170137 109.65 P8Y9M18D 8750 47.66 6891 674.23 154496000 87.97 P8Y9M18D 88604 108.48 P8Y7M6D 0 46.48 <p id="xdx_89A_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zMz0rTq57qAi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted-average assumptions that the Company used to determine the fair value of share options granted were as follows, presented on a weighted average basis:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B4_z7Xyn3TRYj8b" style="display: none">Schedule of Weighted-average Assumptions and Fair Value of Share Options Granted</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20260101__20260331_zOKraQZe5Zr6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20250101__20250331_zSG9Qhs3tsXe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_zQJhVdUwYHYd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Expected volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0915">—</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">95.7</td><td style="width: 1%; text-align: left">%</td></tr> <tr id="xdx_401_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_zyhLyQg9iqTg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0918">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.0</td><td style="text-align: left">%</td></tr> <tr id="xdx_401_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_zzj1WLo6Ya2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0921">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0922">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250101__20250331_zHj6oFRQiWO1" title="Expected term (in years)">5.8</span></td><td style="text-align: left"> </td></tr> </table> 0.957 0.040 P5Y9M18D <p id="xdx_894_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_z6lwblLlVlv4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the Company’s restricted stock activity for the three months ended March 31, 2026:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B0_zFJ2w5LPYXub" style="display: none">Schedule of RSU activity</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Time-based Awards</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of ADSs</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted-Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Grant Date </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; font-weight: bold">Nonvested shares at December 31, 2025</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkPKR2ysxp4d" style="width: 16%; text-align: right" title="Number of ADSs nonvested shares, balance">1,465</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z78B1yYlHaC2" style="width: 16%; text-align: right" title="Weighted average grant date fair value per share, Beginning">30.00</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXImnyhVhqza" style="text-align: right" title="Number of ADSs nonvested shares, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0932">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zuGEx2VDmXP1" style="text-align: right" title="Weighted average grant date fair value per share, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0934">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Forfeited</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zW6Qy9ISY8Q7" style="text-align: right" title="Number of ADSs nonvested shares, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0936">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z0hCWVhEnqv4" style="text-align: right" title="Weighted average grant date fair value per share, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl0938">—</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 0pt">Vested</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_pid_di_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zz1C9uuE4OE4" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of ADSs nonvested shares, Vested">(1,465</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zu6JNttemwk7" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value per share, Vested">30.00</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 2.5pt">Nonvested shares at March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zowR6MsxHPk9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of ADSs nonvested shares, balance"><span style="-sec-ix-hidden: xdx2ixbrl0944">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zSTOkYG9xaS2" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value per share, Ending"><span style="-sec-ix-hidden: xdx2ixbrl0946">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1465 30.00 1465 30.00 1622 129792000 100000 9375 <p id="xdx_890_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zGohJIqgXzvj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B7_zLG69sn9tci1" style="display: none">Schedule of Stock-based Compensation Expense in Statements of Operations</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; display: none; font-weight: bold">($ in thousands)</td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20260101__20260331_z0kBF2WuZMl1" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2026</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20250101__20250331_zBGPQytOo4r" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">($ in thousands)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hsrt--ProductOrServiceAxis__custom--ResearchAndDevelopmentExpensesMember_zdljMyMrGkdb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Research and development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">19</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">191</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hsrt--ProductOrServiceAxis__custom--SellingGeneralAndAdministrativeExpenseMember_ziEVjSIO1GM3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">286</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">824</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_z8XUvmhQwsJ7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">305</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,015</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 19000 191000 286000 824000 305000 1015000 3200000 P2Y7M6D <p id="xdx_804_eus-gaap--FairValueDisclosuresTextBlock_zo7HKqvN4sR9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 8. <span id="xdx_826_zWbf87IMGQtl">Fair Value Measurements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Assets and Liabilities Measured at Fair Value on a Recurring Basis</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p id="xdx_89C_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zg95PGScc5yi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents information about the Company’s financial liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such values:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zqxXLBnQ9Mz5" style="display: none">Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis</span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; display: none; font-weight: bold">(In thousands)</td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z9FAyYjaSdf1" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Total</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zOKw8QxWqBqd" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Level 1</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zjOGkl4tH8Og" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Level 2</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zrXuaGcvY3Yi" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Level 3</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; width: 36%">Liabilities</td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td></tr> <tr id="xdx_400_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--ClassOfWarrantOrRightAxis__custom--AprilTwoThousandTwentyThreePeakBioWarrantsMember_zClt4GHHxPq5" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Warrant liability - April 2023 Peak Bio Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">17</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0976">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0977">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">17</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_zNhR62lmcHVe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0981">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0982">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; display: none; font-weight: bold">(In thousands)</td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zPayaxmcNq6g" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Total</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zbalyV7e0Uai" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Level 1</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zCwCbuBA2ia1" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Level 2</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zcPsL1DWrMlb" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Level 3</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; width: 36%">Liabilities</td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td></tr> <tr id="xdx_409_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--ClassOfWarrantOrRightAxis__custom--AprilTwoThousandTwentyThreePeakBioWarrantsMember_zDz3tE21ngvk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Warrant liability - April 2023 Peak Bio Warrants</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">51</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0986">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0987">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">51</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyTwoSeriesBMember_z07JBo7dqi7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Warrant liability – September 2022 Series B Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0991">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0992">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pn3n3_zMXfO86e27m3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Derivative liability - ELOC</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">230</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0996">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0997">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">230</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_zzaC5Qbjn7f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">291</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1001">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1002">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">291</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_zgAvhIb6w8we" style="display: none; vertical-align: bottom; background-color: White"> <td style="display: none; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Derivative liability</td><td style="display: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right">291</td><td style="display: none; padding-bottom: 2.5pt; text-align: left"> </td><td style="display: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1006">—</span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"> </td><td style="display: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1007">—</span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"> </td><td style="display: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right">291</td><td style="display: none; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A1_zzFpTGkSojv3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s Level 3 liabilities consist of the September 2022 Warrants, the November 2022 Peak Bio Warrants and the April 2023 Peak Bio Warrants, which were determined to be liability-classified instruments, and a derivative liability related to the ELOC Purchase Agreement (described in Note 6). There were no transfers between Level 1, Level 2, and Level 3 during the three months ended March 31, 2026 and the year ended December 31, 2025.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z1g5K15ed7al" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the activity in the warrant liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) during the three months ended March 31, 2026 and 2025:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zHL3j83Knlxb" style="display: none">Schedule of Fair value on Recurring Basis using Unobservable Inputs</span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="display: none"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_4BC_us-gaap--ClassOfWarrantOrRightAxis_custom--SeptemberTwoThousandTwentyTwoSeriesBMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zMJrMlIbt43c" style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_4BC_us-gaap--ClassOfWarrantOrRightAxis_custom--NovemberTwoThousandTwentyTwoPeakBioWarrantsMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zmDasMLYmzn8" style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_4BD_us-gaap--ClassOfWarrantOrRightAxis_custom--AprilTwoThousandTwentyThreePeakBioWarrantsMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zOXf9HgYRF8h" style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td> <td> </td> <td> </td> <td id="xdx_4B2_us-gaap--ClassOfWarrantOrRightAxis_custom--TotalWarrantLiabilityMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zD8cI7HqNImc" style="text-align: right"> </td> <td> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_4BA_us-gaap--ClassOfWarrantOrRightAxis_custom--DerivativeLiabilityMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zQC6SOTVUzta" style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrant Liability </td> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">(In thousands)</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series B</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>November</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Peak Bio</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>April</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Peak Bio</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p></td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Total Warrant Liability</b></td> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Derivative</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liability</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_438_c20250101__20250331_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zA37pemm7E5a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 30%; font-weight: bold">Balance, December 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">181</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">95</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">736</td><td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="text-align: right; width: 10%">1,012</td> <td style="width: 1%"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1016">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zpL68Ou8rF9j" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Change in fair value of liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">30</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1019">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">24</td><td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">54</td> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1022">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_434_c20250101__20250331_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zuJNH9SZg9D6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; font-weight: bold">Balance, March 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">211</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">95</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">760</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">1,066</td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1028">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_439_c20260101__20260331_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_z2isx81H4AU7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Balance, December 31, 2025</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1031">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">51</td><td style="text-align: left"> </td> <td> </td> <td>$</td> <td style="text-align: right">61</td> <td> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">230</td><td style="text-align: left"> </td></tr> <tr id="xdx_438_c20260101__20260331_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zRTzax1gvuf" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="display: none; font-weight: bold">Balance</td><td style="display: none"> </td> <td style="display: none; text-align: left">$</td><td style="display: none; text-align: right">10</td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left">$</td><td style="display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1037">—</span></td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left">$</td><td style="display: none; text-align: right">51</td><td style="display: none; text-align: left"> </td> <td> </td> <td> </td> <td style="text-align: right">61</td> <td> </td><td style="display: none"> </td> <td style="display: none; text-align: left">$</td><td style="display: none; text-align: right">230</td><td style="display: none; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zJe6Eo1xvN08" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Change in fair value of liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(10</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1043">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(34</td><td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(44</td> <td style="padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(230</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_434_c20260101__20260331_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zHcYo3fUmR2g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 2.5pt">Balance, March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1048">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1049">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">17</td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1052">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_43A_c20260101__20260331_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_z9JZMrCpWzii" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="display: none; font-weight: bold; padding-bottom: 2.5pt">Balance</td><td style="display: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1054">—</span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"> </td><td style="display: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1055">—</span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"> </td><td style="display: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right">17</td><td style="display: none; padding-bottom: 2.5pt; text-align: left"> </td> <td> </td> <td> </td> <td style="text-align: right">17</td> <td> </td><td style="display: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1058">—</span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zZoLWrqGzgD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Liability-Classified Warrants</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the warrant liabilities is based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The fair value of the September 2022 Series B Warrants, the November 2022 Peak Bio Warrants and the April 2023 Bio Peak Warrants was determined using the Black-Scholes Option Pricing Model, which uses various assumptions, including (i) fair value of the Company’s ADSs, (ii) exercise price of the warrant, (iii) expected term of the warrant, (iv) expected volatility and (v) expected risk-free interest rate.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_ecustom--DisclosureOfFairValueAssumptionsOfWarrantsTableTextBlock_zX3Q7mfYwvNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below are the assumptions used for the fair value calculations of liability classified warrants as of March 31, 2026 and December 31, 2025:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zdACdk8O5rue" style="display: none">Schedule of Assumptions used for Fair Value Calculations of Warrants</span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="display: none"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_491_20260331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyTwoSeriesBMember_z8anYyRWjTD1" style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_497_20260331__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyTwoWarrantsMember_zgmtPwHJ7L13" style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_49B_20260331__us-gaap--ClassOfWarrantOrRightAxis__custom--AprilTwoThousandTwentyThreeWarrantsMember_zenmqkriw2W8" style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_491_20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyTwoSeriesBMember_zTggAe8MAIs2" style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_498_20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyTwoWarrantsMember_zX1zXvw0U6zf" style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_491_20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--AprilTwoThousandTwentyThreeWarrantsMember_z6kmHYyZwh6d" style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series B</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>November</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Peak Bio</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>April</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Peak Bio</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series B Warrants</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>November</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Peak Bio</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>April</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Peak Bio</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_404_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zMau0zflhihe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Stock (ADS) price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">5.15</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">5.15</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">5.15</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">11.56</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">11.56</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">11.56</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_z88quQLYwjTf" style="vertical-align: bottom; background-color: White"> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">680.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,567.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">81.60</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">680.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,567.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">81.60</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zKxfAmm5Bkc5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected term (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.3</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_ze6WNMwUG0Xb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">115.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">110.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">115.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">105.0</td><td style="text-align: left">%</td></tr> <tr id="xdx_407_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zwXTrHuPs4E" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.7</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.5</td><td style="text-align: left">%</td></tr> <tr id="xdx_40F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zDbmfCB41T7g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1097">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1098">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1099">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1100">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1101">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1102">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z3UzxWUk1MDj" style="display: none; vertical-align: bottom; background-color: White"> <td style="display: none; text-align: left">Warrant outstanding input</td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1104">—</span></td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1105">—</span></td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1106">—</span></td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1107">—</span></td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1108">—</span></td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1109">—</span></td><td style="display: none; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zmAeROzdio87" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Derivative Liability</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The derivative liability related to the ELOC Purchase Agreement (described in Note 6) was originally valued using the Monte Carlo simulation model and as such is considered to be a Level 3 fair value measurement, as the fair value was determined based on significant inputs not observable in the market. The significant unobservable inputs used to determine the fair value were the projected volume weighed average share price at each trading date, and the use of the maximum draw down potential. The fair value of the ELOC Purchase Agreement on December 31, 2025 was $<span id="xdx_905_eus-gaap--DerivativeLiabilities_iI_c20251231_zKLZiHfYLPg3" title="Derivative liabilities">230,000</span> based on the projected stock price of $<span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--TypeOfArrangementAxis__custom--ELOCPurchaseAgreementMember_zF9LKFy5hQBk" title="Derivative liability measurement input">0.29</span>, expected volatility of <span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--TypeOfArrangementAxis__custom--ELOCPurchaseAgreementMember_zpzySVhIJv7l" title="Derivative liability measurement input">102.5</span>%, risk-free rate of <span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--TypeOfArrangementAxis__custom--ELOCPurchaseAgreementMember_zADhlt2JUt" title="Derivative liability measurement input">3.46</span>% and discounted at <span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20251231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember__us-gaap--TypeOfArrangementAxis__custom--ELOCPurchaseAgreementMember_zeyhryyX2yoa" title="Derivative liability measurement input">71.3</span>% for the probability of the Company timely filing all SEC documents and meeting the NASDAQ listing requirements. As of March 31, 2026, the Company determined the fair value of the ELOC Purchase Agreement to have no value based on the projected stock price of $<span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember__us-gaap--TypeOfArrangementAxis__custom--ELOCPurchaseAgreementMember_z52kaXqX3DB9" title="Derivative liability measurement input">5.15</span>, expected volatility of <span id="xdx_908_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--TypeOfArrangementAxis__custom--ELOCPurchaseAgreementMember_zFzTkFf4AGh" title="Derivative liability measurement input">106</span>%, risk-free rate of <span id="xdx_90A_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--TypeOfArrangementAxis__custom--ELOCPurchaseAgreementMember_zd2dRUfr8AHd" title="Derivative liability measurement input">3.73</span>% and discounted at<span id="xdx_90E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20260331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputDiscountRateMember__us-gaap--TypeOfArrangementAxis__custom--ELOCPurchaseAgreementMember_zz6aggWOn2X1" title="Derivative liability measurement input"> 71.3</span>% for the probability of the Company timely filing all SEC documents and meeting the NASDAQ listing requirements. The difference of $<span id="xdx_901_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_pn5n6_c20260101__20260331_zy1kIKe27Mx5" title="Difference in derivative liabilities">0.2</span> million was recognized as a change of fair value of derivative liability in the unaudited condensed consolidated statement of operations and comprehensive loss during the three months ended March 31, 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Assets Measured at Fair Value on a Nonrecurring Basis </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s goodwill and IPR&amp;D are measured at fair value on a nonrecurring basis. These assets are reported at carrying value and are remeasured annually or whenever events or changes in circumstances indicate that their carrying value may not be fully recoverable. When impairment has occurred, the Company records the required charges and adjusts the carrying value as discussed in Note 2. <i>Summary of Significant Accounting Policies</i> of the notes to the consolidated financial statements in the Company’s 2025 Form 10-K. As a result of the impairment analysis performed during the three months ended March 31, 2026, using Level 3 inputs, the Company determined its AKTX-101 IPR&amp;D asset to be $<span id="xdx_904_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pn5n6_c20260101__20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zKxvT108Pzb3" title="Non-cash impairment charge">30.3</span> million and recorded a non-cash impairment charge of $<span id="xdx_904_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_pn5n6_c20260101__20260331_zI6lRvUnbvH1" title="Non-cash impairment charge">3.7</span> million to its AKTX-101 IPR&amp;D asset and determined the fair value of its reporting unit to be less than its carrying value by an amount that resulted in a non-cash impairment charge of $<span id="xdx_90B_eus-gaap--GoodwillImpairmentLoss_pn5n6_c20260101__20260331_zihsAVV23mDh" title="Goodwill impairment charge">8.4</span> million to goodwill. There was <span id="xdx_90E_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_dxL_c20250101__20250331_zfTaFXoIOwGk" title="Impairment charge::XDX::-"><span id="xdx_90F_eus-gaap--GoodwillImpairmentLoss_dxL_c20250101__20250331_zAagf7dBsEEb" title="Goodwill impairment charge::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1137"><span style="-sec-ix-hidden: xdx2ixbrl1139">no</span></span></span></span> impairment charge to the Company’s goodwill and IPR&amp;D assets during the three months ended March 31, 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89C_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zg95PGScc5yi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents information about the Company’s financial liabilities measured at fair value on a recurring basis and indicates the level of the fair value hierarchy used to determine such values:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zqxXLBnQ9Mz5" style="display: none">Schedule of Financial Liabilities Measured at Fair Value on Recurring Basis</span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; display: none; font-weight: bold">(In thousands)</td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20260331__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z9FAyYjaSdf1" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Total</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zOKw8QxWqBqd" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Level 1</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zjOGkl4tH8Og" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Level 2</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20260331__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zrXuaGcvY3Yi" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Level 3</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; width: 36%">Liabilities</td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td></tr> <tr id="xdx_400_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--ClassOfWarrantOrRightAxis__custom--AprilTwoThousandTwentyThreePeakBioWarrantsMember_zClt4GHHxPq5" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 10pt; text-align: left">Warrant liability - April 2023 Peak Bio Warrants</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">17</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0976">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0977">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">17</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_zNhR62lmcHVe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0981">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0982">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; display: none; font-weight: bold">(In thousands)</td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20251231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zPayaxmcNq6g" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Total</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zbalyV7e0Uai" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Level 1</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zCwCbuBA2ia1" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Level 2</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20251231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zcPsL1DWrMlb" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">Level 3</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; width: 36%">Liabilities</td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 12%"> </td><td style="text-align: left; width: 1%"> </td></tr> <tr id="xdx_409_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--ClassOfWarrantOrRightAxis__custom--AprilTwoThousandTwentyThreePeakBioWarrantsMember_zDz3tE21ngvk" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Warrant liability - April 2023 Peak Bio Warrants</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">51</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0986">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0987">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">51</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_hus-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyTwoSeriesBMember_z07JBo7dqi7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Warrant liability – September 2022 Series B Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0991">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0992">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DerivativeLiabilitiesNoncurrent_iI_pn3n3_zMXfO86e27m3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Derivative liability - ELOC</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">230</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0996">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0997">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">230</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_zzaC5Qbjn7f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Total liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">291</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1001">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1002">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">291</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--FinancialLiabilitiesFairValueDisclosure_iI_pn3n3_zgAvhIb6w8we" style="display: none; vertical-align: bottom; background-color: White"> <td style="display: none; padding-left: 20pt; text-align: left; padding-bottom: 2.5pt">Derivative liability</td><td style="display: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right">291</td><td style="display: none; padding-bottom: 2.5pt; text-align: left"> </td><td style="display: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1006">—</span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"> </td><td style="display: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1007">—</span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"> </td><td style="display: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right">291</td><td style="display: none; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 17000 17000 17000 17000 51000 51000 10000 10000 230000 230000 291000 291000 291000 291000 <p id="xdx_896_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z1g5K15ed7al" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the activity in the warrant liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) during the three months ended March 31, 2026 and 2025:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zHL3j83Knlxb" style="display: none">Schedule of Fair value on Recurring Basis using Unobservable Inputs</span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="display: none"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_4BC_us-gaap--ClassOfWarrantOrRightAxis_custom--SeptemberTwoThousandTwentyTwoSeriesBMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zMJrMlIbt43c" style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_4BC_us-gaap--ClassOfWarrantOrRightAxis_custom--NovemberTwoThousandTwentyTwoPeakBioWarrantsMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zmDasMLYmzn8" style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_4BD_us-gaap--ClassOfWarrantOrRightAxis_custom--AprilTwoThousandTwentyThreePeakBioWarrantsMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zOXf9HgYRF8h" style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td> <td> </td> <td> </td> <td id="xdx_4B2_us-gaap--ClassOfWarrantOrRightAxis_custom--TotalWarrantLiabilityMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zD8cI7HqNImc" style="text-align: right"> </td> <td> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_4BA_us-gaap--ClassOfWarrantOrRightAxis_custom--DerivativeLiabilityMember_us-gaap--FairValueByFairValueHierarchyLevelAxis_us-gaap--FairValueInputsLevel3Member_zQC6SOTVUzta" style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Warrant Liability </td> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">(In thousands)</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series B</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>November</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Peak Bio</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>April</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Peak Bio</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p></td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Total Warrant Liability</b></td> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Derivative</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liability</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_438_c20250101__20250331_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zA37pemm7E5a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 30%; font-weight: bold">Balance, December 31, 2024</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">181</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">95</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">736</td><td style="width: 1%; text-align: left"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="text-align: right; width: 10%">1,012</td> <td style="width: 1%"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1016">—</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zpL68Ou8rF9j" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Change in fair value of liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">30</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1019">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">24</td><td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">54</td> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1022">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_434_c20250101__20250331_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zuJNH9SZg9D6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; font-weight: bold">Balance, March 31, 2025</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">211</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">95</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">760</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">1,066</td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1028">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_439_c20260101__20260331_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_z2isx81H4AU7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Balance, December 31, 2025</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1031">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">51</td><td style="text-align: left"> </td> <td> </td> <td>$</td> <td style="text-align: right">61</td> <td> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">230</td><td style="text-align: left"> </td></tr> <tr id="xdx_438_c20260101__20260331_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iS_zRTzax1gvuf" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="display: none; font-weight: bold">Balance</td><td style="display: none"> </td> <td style="display: none; text-align: left">$</td><td style="display: none; text-align: right">10</td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left">$</td><td style="display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1037">—</span></td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left">$</td><td style="display: none; text-align: right">51</td><td style="display: none; text-align: left"> </td> <td> </td> <td> </td> <td style="text-align: right">61</td> <td> </td><td style="display: none"> </td> <td style="display: none; text-align: left">$</td><td style="display: none; text-align: right">230</td><td style="display: none; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_zJe6Eo1xvN08" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Change in fair value of liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(10</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1043">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(34</td><td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">(44</td> <td style="padding-bottom: 1pt">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(230</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_434_c20260101__20260331_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_zHcYo3fUmR2g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; padding-bottom: 2.5pt">Balance, March 31, 2026</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1048">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1049">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">17</td><td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double">$</td> <td style="border-bottom: Black 2.5pt double; text-align: right">17</td> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1052">—</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_43A_c20260101__20260331_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_iE_z9JZMrCpWzii" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="display: none; font-weight: bold; padding-bottom: 2.5pt">Balance</td><td style="display: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1054">—</span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"> </td><td style="display: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1055">—</span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"> </td><td style="display: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right">17</td><td style="display: none; padding-bottom: 2.5pt; text-align: left"> </td> <td> </td> <td> </td> <td style="text-align: right">17</td> <td> </td><td style="display: none; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; display: none; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1058">—</span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 181000 95000 736000 1012000 30000 24000 54000 211000 95000 760000 1066000 10000 51000 61000 230000 10000 51000 61000 230000 -10000 -34000 -44000 -230000 17000 17000 17000 17000 <p id="xdx_89B_ecustom--DisclosureOfFairValueAssumptionsOfWarrantsTableTextBlock_zX3Q7mfYwvNh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Below are the assumptions used for the fair value calculations of liability classified warrants as of March 31, 2026 and December 31, 2025:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B0_zdACdk8O5rue" style="display: none">Schedule of Assumptions used for Fair Value Calculations of Warrants</span></span></span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="display: none"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_491_20260331__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyTwoSeriesBMember_z8anYyRWjTD1" style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_497_20260331__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyTwoWarrantsMember_zgmtPwHJ7L13" style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_49B_20260331__us-gaap--ClassOfWarrantOrRightAxis__custom--AprilTwoThousandTwentyThreeWarrantsMember_zenmqkriw2W8" style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_491_20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--SeptemberTwoThousandTwentyTwoSeriesBMember_zTggAe8MAIs2" style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_498_20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--NovemberTwoThousandTwentyTwoWarrantsMember_zX1zXvw0U6zf" style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td id="xdx_491_20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--AprilTwoThousandTwentyThreeWarrantsMember_z6kmHYyZwh6d" style="display: none; text-align: right"> </td><td style="display: none; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="10" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series B</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>November</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Peak Bio</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>April</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Peak Bio</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series B Warrants</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>November</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Peak Bio</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p></td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>April</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Peak Bio</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants</b></span></p></td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_404_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zMau0zflhihe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Stock (ADS) price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">5.15</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">5.15</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">5.15</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">11.56</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">11.56</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">11.56</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember_z88quQLYwjTf" style="vertical-align: bottom; background-color: White"> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">680.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,567.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">81.60</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">680.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,567.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">81.60</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zKxfAmm5Bkc5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected term (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.5</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.7</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.3</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_ze6WNMwUG0Xb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">115.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">110.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">115.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">105.0</td><td style="text-align: left">%</td></tr> <tr id="xdx_407_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zwXTrHuPs4E" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.8</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.7</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3.5</td><td style="text-align: left">%</td></tr> <tr id="xdx_40F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zDbmfCB41T7g" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1097">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1098">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1099">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1100">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1101">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1102">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_hus-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z3UzxWUk1MDj" style="display: none; vertical-align: bottom; background-color: White"> <td style="display: none; text-align: left">Warrant outstanding input</td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1104">—</span></td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1105">—</span></td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1106">—</span></td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1107">—</span></td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1108">—</span></td><td style="display: none; text-align: left"> </td><td style="display: none"> </td> <td style="display: none; text-align: left"> </td><td style="display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1109">—</span></td><td style="display: none; text-align: left"> </td></tr> </table> 5.15 5.15 5.15 11.56 11.56 11.56 680.00 1567.20 81.60 680.00 1567.20 81.60 3.5 1.6 2.1 3.7 1.8 2.3 100.0 115.0 110.0 100.0 115.0 105.0 3.8 3.8 3.8 3.7 3.5 3.5 230000 0.29 102.5 3.46 71.3 5.15 106 3.73 71.3 200000 30300000 3700000 8400000 <p id="xdx_807_eus-gaap--EarningsPerShareTextBlock_zm4CEna4bMk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 9. <span id="xdx_82A_z5uLtZmiJTy3">Net Loss per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following potential dilutive securities, presented based on amounts outstanding at the end of each reporting period, have been excluded from the calculation of diluted net loss per share because including them would have had an anti-dilutive impact:</span></p> <p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zVDaSwokJmr9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zKtTyCPYRKad" style="display: none">Schedule of Antidilutive Securities Excluded From Computation of Earnings Per Share</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20260101__20260331_z6y3erkfUSh1" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2026</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20250101__20250331_zium6FBJ9s16" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zsvqXblvbFch" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">12,359,566,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">14,390,286,688</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zq9KRFGYKsu9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">129,792,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1149">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zwNGW2Zj28u6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">106,949,459,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,325,911,500</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zs7YBDoT5agi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Convertible notes</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,832,118,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1155">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zZreknkq5hw3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">121,270,935,200</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">43,716,198,188</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zqd7P4OXIf2c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zVDaSwokJmr9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zKtTyCPYRKad" style="display: none">Schedule of Antidilutive Securities Excluded From Computation of Earnings Per Share</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="display: none"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20260101__20260331_z6y3erkfUSh1" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2026</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20250101__20250331_zium6FBJ9s16" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zsvqXblvbFch" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">12,359,566,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">14,390,286,688</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zq9KRFGYKsu9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Restricted stock units</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">129,792,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1149">—</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zwNGW2Zj28u6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">106,949,459,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">29,325,911,500</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zs7YBDoT5agi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Convertible notes</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,832,118,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1155">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zZreknkq5hw3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">121,270,935,200</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">43,716,198,188</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 12359566000 14390286688 129792000 106949459200 29325911500 1832118000 121270935200 43716198188 <p id="xdx_800_eus-gaap--IncomeTaxDisclosureTextBlock_zqQm7UHFjMA7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 10. <span id="xdx_829_zpiCGcutivIj">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASC 270, <i>Interim Reporting</i>, and ASC 740, <i>Income Taxes</i>, the Company is required at the end of each interim period to determine the best estimate of its annual effective tax rate and then apply that rate in providing for income taxes on a current year-to-date (interim period) basis. The Company recorded an income tax benefit of $<span id="xdx_906_eus-gaap--IncomeTaxExpenseBenefit_iN_pn5n6_di_c20260101__20260331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ImpairmentLossOnOtherIntangibleAssetsMember_zDsqe4ra4Oe9" title="Income tax benefit">0.8</span> million for the three months ended March 31, 2026 in connection with the impairment loss on other intangible assets. For the three months ended March 31, 2026 and 2025, the Company recorded <span id="xdx_901_eus-gaap--IncomeTaxExpenseBenefit_iN_dio_c20260101__20260331__us-gaap--OtherCommitmentsAxis__custom--ExpectedCurrentYearLossAndHistoricalLossMember_zpQulSz2uL3a" title="Income tax expense"><span id="xdx_90E_eus-gaap--IncomeTaxExpenseBenefit_iN_dio_c20250101__20250331__us-gaap--OtherCommitmentsAxis__custom--ExpectedCurrentYearLossAndHistoricalLossMember_zolBgrpin257" title="Income tax expense">no</span></span> tax expense or benefit due to the expected current year loss and its historical losses. The Company has not recorded its net deferred tax asset as of either March 31, 2026 or December 31, 2025 because it maintained a full valuation allowance against all deferred tax assets as of these dates as management has determined that it is not more likely than not that the Company will realize these future tax benefits. As of March 31, 2026 and December 31, 2025, the Company had <span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20260331_zHIpIkB4V3gb" title="Unrecognized tax benefits"><span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20251231_zFqClEtNs1je" title="Unrecognized tax benefits">no</span></span> uncertain tax positions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> -800000 -0 -0 0 0 <p id="xdx_801_eus-gaap--SegmentReportingDisclosureTextBlock_z5N3KOIF2xh8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 11. <span id="xdx_825_zTdSMGljnEb3">Segment Information</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company manages its operations as a single<span id="xdx_903_eus-gaap--NumberOfOperatingSegments_uInteger_c20260101__20260331_zmPJeRpHAxI9" style="display: none"><span id="xdx_90F_eus-gaap--NumberOfReportableSegments_uInteger_c20260101__20260331_zPMTHJ9GQSyb" title="Number of reportable segments">1</span></span> operating segment for the purpose of assessing performance, making operating decisions and allocating resources, resulting in a single reportable segment. The Company has determined that its Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer. The Company’s CODM reviews the Company’s financial information on a consolidated basis for the purpose of allocating resources and assessing financial performance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has assembled a portfolio of preclinical product candidates that aim to develop next-generation precision bifunctional ADCs for the treatment of cancer. The Company has not generated any revenue since its inception and does not expect to generate any revenue from the sale of products in the near future. The Company primarily incurs expenses in connection with the research and development of its product candidates as well as general and administrative costs consisting of salaries and related costs for personnel in executive, finance, and administrative functions, as well as consulting, restructuring and merger-related expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_eus-gaap--SegmentReportingExpenseInformationUsedByCodmDescription_c20260101__20260331_zGviotsoeJs6" title="Segment reporting description">The key measure of segment profit or loss that the CODM uses to allocate resources and assess performance is the Company’s consolidated net loss, as reported on the consolidated statements of operations and comprehensive loss. In addition, the CODM is regularly provided the following significant segment expense categories which are reviewed against budgeted expectations to assist in resource allocation decision-making:</span></span></p> <p id="xdx_89F_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zqafwLZlQnRb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zwF1LN3upu28" style="display: none">Schedule of Significant Segment Expense Categories</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; display: none; font-weight: bold">(In thousands)</td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20260101__20260331_zyTpc06lXk6d" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2026</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20250101__20250331_zH60qC47O6Bh" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--ADCPreClinicalDevelopmentMember__us-gaap--StatementBusinessSegmentsAxis__custom--SignificantSegmentExpenseCategoryMember_zGe3tyqmD97g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">ADC preclinical development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(1,237</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(17</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--HSCTTMAAK901ProgramMember__us-gaap--StatementBusinessSegmentsAxis__custom--SignificantSegmentExpenseCategoryMember_zg4TMlbKFTu7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">HSCT-TMA (AK901) clinical program expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1184">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(62</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--ChemistryManufacturingAndControlMember__us-gaap--StatementBusinessSegmentsAxis__custom--SignificantSegmentExpenseCategoryMember_zh1pY99g8q88" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Chemistry, manufacturing, and control</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1187">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(28</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--OtherExternalDevelopmentExpenseIncomeMember__us-gaap--StatementBusinessSegmentsAxis__custom--SignificantSegmentExpenseCategoryMember_zU5OjS11asSf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other external development expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(17</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(98</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--InternalAndOtherResearchAndDevelopmentExpenseMember__us-gaap--StatementBusinessSegmentsAxis__custom--SignificantSegmentExpenseCategoryMember_zSKOV7bbvyz4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Internal and other research and development expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(186</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(417</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--GeneralAndAdministrativeExpense_hus-gaap--StatementBusinessSegmentsAxis__custom--SignificantSegmentExpenseCategoryMember_zZsPTHbiLLb6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">General and administrative expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,883</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,888</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_hus-gaap--StatementBusinessSegmentsAxis__custom--SignificantSegmentExpenseCategoryMember_zZ19ejercSG6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment loss on other intangible assets</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,700</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1200">—</span></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--GoodwillImpairmentLoss_hus-gaap--StatementBusinessSegmentsAxis__custom--SignificantSegmentExpenseCategoryMember_zaFEHoMKR7wd" style="vertical-align: bottom; background-color: White"> <td><p style="margin: 0">Impairment loss on goodwill</p></td> <td> </td> <td> </td> <td style="text-align: right">(8,430</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1203">—</span></td> <td> </td></tr> <tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--StatementBusinessSegmentsAxis__custom--SignificantSegmentExpenseCategoryMember_zbEYcpHzZa57" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Stock-based compensation expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(305</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,015</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--SegmentReportingOtherItemAmount_hus-gaap--StatementBusinessSegmentsAxis__custom--SignificantSegmentExpenseCategoryMember_zPFEZClTa80i" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other segment items <span id="xdx_F49_zrnZ90icfCp1"><i>(1)</i></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">444</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(180</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--DeferredIncomeTaxExpenseBenefit_hus-gaap--StatementBusinessSegmentsAxis__custom--SignificantSegmentExpenseCategoryMember_zx0lqA3bmdG" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Deferred tax benefit</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">859</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1212">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--NetIncomeLoss_zJ9FTBqZPdcc" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(14,455</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,705</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F06_z1I5PNC4nr0g">(1)</i></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F1E_zBZQ60vZl2O3">Other segment items include interest expense, change in fair value of warrant liabilities, change in fair value of derivative liability, and net foreign currency exchange gains (losses) as reported in the Company’s condensed consolidated statements of operations and comprehensive loss.</i></span></td> </tr></table> <p id="xdx_8A9_zORrOsTHQ3i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets regularly provided to the CODM are consistent with those reported on the consolidated balance sheets with particular emphasis on the Company’s available liquidity, including its cash and restricted cash. All of the Company’s tangible assets are held in the United States.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1 1 The key measure of segment profit or loss that the CODM uses to allocate resources and assess performance is the Company’s consolidated net loss, as reported on the consolidated statements of operations and comprehensive loss. In addition, the CODM is regularly provided the following significant segment expense categories which are reviewed against budgeted expectations to assist in resource allocation decision-making: <p id="xdx_89F_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zqafwLZlQnRb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zwF1LN3upu28" style="display: none">Schedule of Significant Segment Expense Categories</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; display: none; font-weight: bold">(In thousands)</td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20260101__20260331_zyTpc06lXk6d" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2026</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td><td style="display: none; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20250101__20250331_zH60qC47O6Bh" style="border-bottom: Black 1pt solid; display: none; font-weight: bold; text-align: center">2025</td><td style="display: none; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold">(In thousands)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--ADCPreClinicalDevelopmentMember__us-gaap--StatementBusinessSegmentsAxis__custom--SignificantSegmentExpenseCategoryMember_zGe3tyqmD97g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">ADC preclinical development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(1,237</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(17</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--HSCTTMAAK901ProgramMember__us-gaap--StatementBusinessSegmentsAxis__custom--SignificantSegmentExpenseCategoryMember_zg4TMlbKFTu7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">HSCT-TMA (AK901) clinical program expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1184">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(62</td><td style="text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--ChemistryManufacturingAndControlMember__us-gaap--StatementBusinessSegmentsAxis__custom--SignificantSegmentExpenseCategoryMember_zh1pY99g8q88" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Chemistry, manufacturing, and control</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1187">—</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(28</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--OtherExternalDevelopmentExpenseIncomeMember__us-gaap--StatementBusinessSegmentsAxis__custom--SignificantSegmentExpenseCategoryMember_zU5OjS11asSf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other external development expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(17</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(98</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_eus-gaap--ResearchAndDevelopmentExpense_hsrt--ProductOrServiceAxis__custom--InternalAndOtherResearchAndDevelopmentExpenseMember__us-gaap--StatementBusinessSegmentsAxis__custom--SignificantSegmentExpenseCategoryMember_zSKOV7bbvyz4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Internal and other research and development expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(186</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(417</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--GeneralAndAdministrativeExpense_hus-gaap--StatementBusinessSegmentsAxis__custom--SignificantSegmentExpenseCategoryMember_zZsPTHbiLLb6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">General and administrative expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,883</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,888</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--ImpairmentOfIntangibleAssetsExcludingGoodwill_hus-gaap--StatementBusinessSegmentsAxis__custom--SignificantSegmentExpenseCategoryMember_zZ19ejercSG6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment loss on other intangible assets</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,700</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1200">—</span></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_407_eus-gaap--GoodwillImpairmentLoss_hus-gaap--StatementBusinessSegmentsAxis__custom--SignificantSegmentExpenseCategoryMember_zaFEHoMKR7wd" style="vertical-align: bottom; background-color: White"> <td><p style="margin: 0">Impairment loss on goodwill</p></td> <td> </td> <td> </td> <td style="text-align: right">(8,430</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1203">—</span></td> <td> </td></tr> <tr id="xdx_407_eus-gaap--AllocatedShareBasedCompensationExpense_hus-gaap--StatementBusinessSegmentsAxis__custom--SignificantSegmentExpenseCategoryMember_zbEYcpHzZa57" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Stock-based compensation expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(305</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,015</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--SegmentReportingOtherItemAmount_hus-gaap--StatementBusinessSegmentsAxis__custom--SignificantSegmentExpenseCategoryMember_zPFEZClTa80i" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Other segment items <span id="xdx_F49_zrnZ90icfCp1"><i>(1)</i></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">444</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(180</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--DeferredIncomeTaxExpenseBenefit_hus-gaap--StatementBusinessSegmentsAxis__custom--SignificantSegmentExpenseCategoryMember_zx0lqA3bmdG" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: left">Deferred tax benefit</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">859</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1212">—</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--NetIncomeLoss_zJ9FTBqZPdcc" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(14,455</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,705</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F06_z1I5PNC4nr0g">(1)</i></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i id="xdx_F1E_zBZQ60vZl2O3">Other segment items include interest expense, change in fair value of warrant liabilities, change in fair value of derivative liability, and net foreign currency exchange gains (losses) as reported in the Company’s condensed consolidated statements of operations and comprehensive loss.</i></span></td> </tr></table> -1237000 -17000 -62000 -28000 -17000 -98000 -186000 -417000 -1883000 -1888000 -3700000 -8430000 -305000 -1015000 444000 -180000 859000 -14455000 -3705000 <p id="xdx_80D_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zR91NMy30URe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 12.<span id="xdx_82C_zbEwLssytZvd"> Related Party Transactions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2024, the Company assumed an amount due to an entity in which the Company’s Chairman, Dr. Hoyoung Huh, is a director. As of March 31, 2026, and December 31, 2025, the amounts due totalled less than $<span id="xdx_90C_ecustom--AmountDueToRelatedParty_iI_pn5n6_c20260331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zYQ0ot3EYg55" title="Amount due to related party"><span id="xdx_907_ecustom--AmountDueToRelatedParty_iI_pn5n6_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zzm4i9rodpsf" title="Amount due to related party">0.1</span></span> million and are included in accounts payable in the Company’s condensed consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 100000 100000 <p id="xdx_80A_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zBs7rn4UifKc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 13. <span id="xdx_825_zxAIyyzWbEB5">Commitments and Contingencies</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Leases</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company currently leases office space for our U.S. headquarters on a short-term basis. The Company leases its U.S. headquarters virtual office, located in Tampa, Florida, on a month-to-month basis. The Company also leases laboratory space, located in San Francisco, California, on a month-to-month basis and is cancellable anytime with 60 days’ notice. The Company is not party to any material lease agreements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For each of the three months ended March 31, 2026, and 2025, the Company incurred lease costs of less than $<span id="xdx_90B_eus-gaap--OperatingLeaseCost_pn5n6_c20250101__20250331__srt--RangeAxis__srt--MaximumMember_zAgw7OOJ3mR8" title="Lease costs"><span id="xdx_90B_eus-gaap--OperatingLeaseCost_pn5n6_c20260101__20260331__srt--RangeAxis__srt--MaximumMember_zIJYefSBvxJi" title="Lease costs">0.1</span></span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Employee Benefit Plans</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company adopted an employee benefit plan under Section 401(k) of the Internal Revenue Code for its U.S.-based employees. The plan allows employees to make contributions up to a specified percentage of their compensation. <span id="xdx_901_eus-gaap--DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_c20260101__20260331__us-gaap--LossContingenciesByNatureOfContingencyAxis__us-gaap--WithdrawalFromMultiemployerDefinedBenefitPlanMember_zvsoQufdJZRe" title="Description of employee benefit plans">Under the plan, the Company matches 100% of employees’ contributions up to 5% of the annual eligible compensation contributed by each employee, subject to Internal Revenue Code limitations.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_c20260101__20260331__us-gaap--LossContingenciesByNatureOfContingencyAxis__us-gaap--WithdrawalFromMultiemployerDefinedBenefitPlanMember__us-gaap--RetirementPlanSponsorLocationAxis__us-gaap--ForeignPlanMember_zY8TM76y0glk" title="Description of employee benefit plans">The Company also adopted a defined contribution pension scheme which allows for U.K. employees to make contributions and provides U.K. employees with a Company contribution of 10% of compensation, subject to U.K. law.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During each of the three months ended March 31, 2026, and 2025, the Company charged less than $<span id="xdx_905_eus-gaap--OperatingExpenses_pn5n6_c20250101__20250331__srt--RangeAxis__srt--MaximumMember__us-gaap--LossContingenciesByNatureOfContingencyAxis__us-gaap--WithdrawalFromMultiemployerDefinedBenefitPlanMember_zwHiaFBtlJ6d" title="Operating expenses"><span id="xdx_901_eus-gaap--OperatingExpenses_pn5n6_c20260101__20260331__srt--RangeAxis__srt--MaximumMember__us-gaap--LossContingenciesByNatureOfContingencyAxis__us-gaap--WithdrawalFromMultiemployerDefinedBenefitPlanMember_zlCqA2BLtR53" title="Operating expenses">0.1</span></span> million to operating expenses related to the Company’s contributions to employee benefit plans.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Bayer Acquisition Agreement</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2024, the Company assumed an assignment, license, development and commercialization agreement dated March 17, 2017 with Bayer (the “Bayer Acquisition Agreement”), to acquire from Bayer all right, title and interest in and to PHP-303, including each and every invention and any priority rights relating to its patents.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the Bayer Acquisition Agreement, the Company is committed to pay certain development and regulatory milestones up to an aggregate amount of $<span id="xdx_906_eus-gaap--BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_iI_c20260331__us-gaap--BusinessAcquisitionAxis__custom--BayerAcquisitionAgreementMember_z8tdyX9XG2Pl" title="Development and regulatory milestone committed payment amount">23,500,000</span> and high single digit royalties based on the sale of products developed based on the licensed compound. Royalties will be payable on a licensed product-by-licensed product and country-by-country basis until the later of ten years after the first commercial sale of such licensed product in such country and expiration of the last patent covering such licensed product in such country that would be sufficient to prevent generic entry.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either party may terminate the Bayer Acquisition Agreement upon prior written notice for the other party’s material breach that remains uncured for a specified period of time or insolvency. Bayer agreed not to assert any Bayer intellectual property rights that were included in the scope of the Bayer Acquisition Agreement against the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company incurred <span id="xdx_901_eus-gaap--BusinessCombinationContingentConsiderationLiability_iI_dc_c20260331__us-gaap--BusinessAcquisitionAxis__custom--BayerAcquisitionAgreementMember_zaZ76kpyI5f6" title="Acquisition Agreement incurred expenses">zero</span> expenses under this agreement as no milestones have been achieved since inception, and no products were sold from inception through March 31, 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legal Proceedings</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2025, a former employee of Peak Bio CA, Inc. subsidiary filed a claim stating that they are entitled to certain discretionary bonuses from 2022 totalling less than $<span id="xdx_907_eus-gaap--AccruedBonusesCurrentAndNoncurrent_iI_pn5n6_c20250531__srt--RangeAxis__srt--MaximumMember_zbN1JJ92lbOe" title="Discretionary Bonus">0.1</span> million. The Company denies the former employee’s claim and intends to defend itself.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounts Payable Settlements</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the three months ended March 31, 2026, the Company entered into settlement agreements with vendors for the settlement of outstanding payables. This resulted in a gain on settlement of current liabilities of less than $<span id="xdx_909_ecustom--GainOnSettlementOfCurrentLiabilities_pn5n6_c20260101__20260331__us-gaap--TypeOfArrangementAxis__custom--SettlementAgreementMember_z7DQqNoRgZZh" title="Gain on settlement of current liabilities">0.1</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million, which is reflected in the unaudited condensed consolidated statement of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p> 100000 100000 Under the plan, the Company matches 100% of employees’ contributions up to 5% of the annual eligible compensation contributed by each employee, subject to Internal Revenue Code limitations. The Company also adopted a defined contribution pension scheme which allows for U.K. employees to make contributions and provides U.K. employees with a Company contribution of 10% of compensation, subject to U.K. law. 100000 100000 23500000 0 100000 100000 false false false false false false Includes both vested stock options as well as unvested stock options for which the requisite service period has not been rendered but that are expected to vest based on achievement of a service condition. Other segment items include interest expense, change in fair value of warrant liabilities, change in fair value of derivative liability, and net foreign currency exchange gains (losses) as reported in the Company’s condensed consolidated statements of operations and comprehensive loss.